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The overlap between of malaria and iron deficiency makes it difficult to treat both 
conditions since iron supplementation can increase malaria and malaria decreases iron 
absorption. Iron chelators have proven antiparasitic activity. We characterized the 
antimalarial pharmacodynamics of the novel iron chelator FBS0701 in Plasmodium and 
evaluated the effect of the type and timing of iron diet on murine malaria during iron 
repletion.   FBS0701, (S)3’’-(HO)-desazadesferrithiocin-polyether [DADFT-PE], is an 
oral iron chelator to treat transfusional iron overload.  We showed that FBS0701 enter the 
erythrocytes and removes intracellular iron. FBS0701 reduced hepatic parasite load. 
FBS0701 interfered with artemisinin but was additive with chloroquine or quinine 
inhibition in the blood stage and with primaquine in the hepatic stage. FBS0701 killed 
early and late stage P. falciparum gametocytes. A single oral dose one day after infection 
cured P. yoelii 17XL infected mice.  We studied the importance of iron 
compartmentalization on hepatic malaria infection on transgenic anemic mice: mice 
overexpressing hepcidin with reduced iron stores in the liver and hemoglobin deficient 
mice with normal hepatic iron stores. We found lower parasites on mice overexpressing 
hepcidin compared to non-anemic control mice (with normal liver iron). Parasite loads on 
hemoglobin deficient mice were not significantly different to non-anemic control mice. 
Finally, we studied the effect of low and high iron diets on the hepatic stage of murine 
malaria and the interplay of hepcidin with the hepatic infection levels. We used mice that 
were both anemic and iron deficient as well as non-anemic mice and gave both groups 
low and high iron diets for 2 and 6 weeks. Our results showed that high iron diets 
increased liver stage parasites in non-anemic mice and that iron supplementation 
iii 
 
predominated over a negative hepcidin effect. We partially replicated in mice the human 
findings from the Pemba study. In conclusion, FBS0701 could be useful as malarial 
prophylactic or in combination with other antimalarials. FBS0701 has the potential to be 
used a transmission blocking agent. Increasing liver stage may synergize with blood stage 
increases after iron supplementation. Therefore, iron supplementation programs in 
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1.1  Epidemiology  
Over a billion people have nutritional iron deficiency worldwide. Africa and 
Southeast Asia account for nearly 70% of both global mortality and disability adjusted 
life years lost pe r year. There is also significant overlap between regions of malaria 
infection and nutritional iron deficiency manifested by anemia (Figures 1.1,  1.2 and 1.3).  
Malaria is endemic in tropical subtropical regions, affecting especially developing 
countries. Approximately 3 billion people are at risk of infection and more than 240 
million progress yearly towards symptomatic malaria
1
. From 2000 to 2010 there was a 
reduction in the number of cases by 85% in 34 of the countries that are constant fighters 
to eliminate malaria. More than 80% of deaths occur in Sub-Saharan Africa
2,3
. P. 
falciparum is responsible for most of the burden of disease and then P. vivax. P. 
falciparum is predominant in Africa, New Guinea and Hispaniola whereas P. vivax is 
predominant in the Americas and Western Pacific
3,4
. Both species are equally present in 
India, eastern Asia and Oceania. P. malariae and P. ovale are both uncommon, with P. 
malariae found worldwide and P. ovale principally in Africa.  
Malaria epidemiology varies within small geographic areas. According to 
parasitemia rates or spleen rates in children between 2 and 9 years old, the epidemiology 
is classified as hypoendemic (< 10%), mesoendemic (11 – 50%), hyperendemic (51-74%) 
and holoendemic (> 75%). Malaria transmission is directly proportional to the vector 
density, the number of human bites per day per mosquito and the probability of the 





In addition to the overlap between malaria and nutritional iron deficiency, malaria as 
a chronic infectious disease, can further decrease iron uptake from the intestine, 
contribute to restricted erythropoiesis, sequester bioavailable iron in ferritin stores and 
induce lysis of infected and uninfected red blood cells
6
. Distinguishing malaria 






























































1.2 Etiology and Pathogenesis 
In general, the Plasmodium parasite progresses from mosquito stage, to hepatic 
stage and finally to blood stage. This last stage contributes to anemia.  
Typically infection begins with the bite to a person by a Plasmodium spp. infected 
female Anopheles mosquito. Humans can be infected with P. falciparum, P. vivax, P. 
ovale and P. malariae. Incubation times vary depending on the species. Parasites in the 
form of sporozoites enter the bloodstream and reach the liver where they multiply 
asexually. Both hepcidin and iron concentration modulate the number of parasites in the 
liver
9
. Merozoites emerge from hepatocytes and enter the bloodstream invading and 
multiplying in red blood cells
10
.  
P. vivax and P. ovale have a hypnozoite form and the parasite can linger in the 
liver for months before inducing relapse after initial infection. During erythrocytic 
asexual multiplication a few merozoites will develop into gametocytes (immature sexual 
form). When the mosquito bites, it ingest gametocytes that develop into gametes (mature 
sexual forms) and then into ookinetes that will cross the midgut wall of the Anopheles. 
Oocysts will rupture and release sporozoites that will reach the salivary glands. The 
infection cycle begins again with a new bite to another person.  
The erythrocytic stage is responsible for the symptoms of malaria clinical disease.  
Classically malaria is the triad of fever, anemia and splenomegaly. Other symptoms of 
malaria include headache, fever, muscle aches, anorexia, chills, thrombocytopenia, 





.  P. falciparum can cause severe or fatal disease by inducing the formation of 
knobs containing the protein PfEMP-1 on the erythrocytic membrane, which binds to 
receptors on the endothelial cells in post-capillary venules.  The cytoadherence and 
sequestration of erythrocytes and the formation of rosettes through the sticking of 
infected and uninfected cells causes obstruction of the microvessels
11
. Sequestration in 
the vasculature allows parasites to reach a high biomass in the host. 
12
 
Plasmodium triggers anemia by: lysis of infected erythrocytes, increased 
clearance of uninfected erythrocytes by the spleen; and suppressing hematopoiesis after 
the release of cytokines caused by erythrocytic lysis or hemozoin
13
.     
 
1.3  Iron importance for living organisms 
Due to its oxidation states and transition metal characteristics, iron is important in 
metabolic reactions in all cells, including pathogens such viruses, bacteria, fungi and 
protozoa
14,15
. Iron is essential for hematopoesis, oxygen delivery, neurological function, 
immune function and cognitive and physical development
16
. Proteins that incorporate 
iron include hemoglobin, myoglobin, catalase, cytochromes and iron flavoproteins like 
xanthine oxidase, succinate dehydrogenase and NAD dehydrogenase
17
. The metal is also 
important for function of organelles such as the mitochondria and chloroplast, for 
electron transport, iron sulfur clusters and half of the enzymes of the tricarboxylic acid 





Iron is rarely found as a free cation, as it can produce oxygen radicals that damage 
membranes and proteins. In the cells, iron is stored and transported through proteins that 
are regulated to ensure iron balance. Some of these proteins are ferritin, transferrin, 
aconitases, heme synthesis enzymes, iron transporters like the divalent metal-ion 
transporter (DMT) or ferroportin
17
. These proteins have a post translational regulation.   
 
1.3.1 Iron homeostasis in humans 
Human hemoglobin contains around 1700 mg of iron in adult females and 2400 
mg of iron in adult males. Macrophages of the spleen and liver have around 600 mg of 
iron in ferritin and hemosiderin, the bone marrow around 300 mg and the liver 
parenchyma 1000 mg and muscles and other cells around 400 mg. The labile pool bound 
to transferrin in the plasma is around 3-4 mg. Bioavailable iron for daily erythropoiesis is 
approximately 20 mg. Iron from diet accounts for 10-15 mg of which 1 mg is absorbed 
and 1 mg is lost in exfoliation of cells of the skin and gastrointestinal tract
18
. There is no 
known mechanism for regulated iron excretion.    
 
1.3.2  Iron physiology 
The absorption of iron into enterocytes is carried out by DMT-1
19
. Iron bound to 
transferrin in the plasma enters to cells through transferrin receptor. Iron is exported to 
the plasma through ferroportin present in duodenal enterocytes, macrophages, 
hepatocytes, astrocytes and syncytiotrophoblasts
17
. This export is facilitated by the 
10 
 
multicopper feroxidases, hephaestin or ceruloplasmin
20
. Cells need iron basically for 
DNA synthesis and mitochondrial function.    
 
1.3.3 Iron deficiency 
Iron deficiency affects around 500 million individuals, mainly half of children and 
pregnant women worldwide
21
. Low iron can be caused by poor dietary intake, chronic 
blood loss, transfer of iron to fetus in pregnancy and hemoglubinuria
18
. Iron deficiency 
progresses from low iron in plasma and low transferrin saturation without anemia to low 
levels of hemoglobin and hypochromic and microcytic anemia. Cellular ferritin 
diminishes but soluble and surface transferrin receptors and zinc protoporphyrin IX 
increase
22
.   The body slowly decreases iron in hemoglobin to preserve bioavailable iron 
for brain function. 
 
1.4  Iron metabolism in the Plasmodium parasite 
Plasmodium has an absolute requirement for iron. Once inside the red blood cell, 
Plasmodium has to get rid of the excess heme iron from hemoglobin degradation and 
obtain iron for its own metabolism
18
. At the erythrocytic stage, the parasite ingests 60-
80% of the 5 mM hemoglobin store of the erythrocyte for its amino acid supply
23
. 
Because the parasite does not have a functional heme oxygenase or iron storage proteins, 
it handles reactive heme iron by sequestering the toxic heme, capable  of oxygen radical 
production by the Fenton reaction, to the chemically oxidation/reduction inert hemozoin 
11 
 
crystal inside an oxygen-rich vacuole
23
. Interestingly in parallel the parasite syntheses its 
own heme
24
. This heme synthesis is not required for erythrocyte stages but is essential for 
mosquito or liver stages without access to hemoglobin. The asexual stage undergoes a 
rapid proliferation - replication of DNA and therefore requires the activity of the iron 
requiring ribonucleotide reductase for synthesis of nucleotides
25
. Although being in an 
environment with 20 mM heme iron inside the erythrocyte, iron chelators at low 
concentrations can decrease the development of the parasite. The amount of iron 
bioavailable for the parasite is low and key for its survival
25
.       
 
1.4.1   Iron sources for Plasmodium  
Iron is needed for DNA synthesis, glycolysis, pyrimidine synthesis, heme 
synthesis and electron transport
18
. Chelation could potentially target the following: 
extracellular iron from transferrin or free iron in the media, intracellular iron bound to 
low molecular weight proteins, heme iron or erythrocyte ferritin iron
25
. Studies excluded 
the use of transferrin for iron uptake
26,27
. Removal of free iron by dialysis below 1 µM
28
 
or the use of impermeable dextran-DFO did not have an effect on parasite growth
29
. The 
erythrocytic labile iron pool was identified by calcein and was also found to be calcein 
labile in the parasite. Studies also showed that uninfected erythrocytes had higher total 
amount of labile iron pool compared to infected cells
30
. Erythrocytic ferritin can store up 
to 4500 iron molecules
31
. It was thought that the erythrocyte ferritin could go to the 
digestive vacuole along with hemoglobin and be digested by proteases releasing iron. 
Studies proved that iron is transported across the plasma membrane directly but not 
12 
 
through the digestive vacuole or deriving from heme
18
. In addition, the parasite sequence 
database does not report orthologs to ferroportin, ferritin, methallothione, ferroxamine-
based transport systems, ferredoxin or bacterial iron siderophores
32
.            
 
1. 5 Hepcidin and regulation of iron on humans 
In humans iron for erythrocyte production is obtained by two ways. Daily, 
humans absorb from diet 1-10 mg of iron approximately and most is incorporated into 
heme during erythropoiesis. Macrophages phagocytize and degrade old erythrocytes 
carrying around 25 mg daily that return to the circulation on transferrin 
33
. The cycle of 
iron is regulated by a hormone called hepcidin. Iron transfer from enterocytes and 
recycling of iron from macrophages to serum is carried by a membrane transporter called 
ferroportin. Hepcidin binds to ferroportin inducing the phosphorylation, ubiquination and 
degradation of the transporter inhibiting iron export to the systemic circulation
34
.  
Hepcidin-ferroportin interaction is the dominant regulator of iron homeostasis in 
vertebrates and in this way hepcidin is considered the master iron regulator. Hepcidin 
regulates iron traffic not only at the level of dietary absorption and recycling but also at 
intracellular iron stores
33
.     
Hepcidin is poorly expressed in the heart and brain and is highly expressed in the 
liver as a prehormone of 84 amino acids. The prehormone is cleaved by a furin-like 
convertase to a 25-amino acid mature peptide (amino acids 60-84), containing eight 
cysteine residues that form disulfide bonds
35
. Hepcidin structure is a beta hairpin. Other 
13 
 
less active forms such 23 peptides are formed by cleavage of a specific dipeptidase and is 
required for cleavage to the 20- amino acid form
36
. With each shorter form the peptide 
losses critical N-terminal amino acids that decrease the ability of hepcidin to bind 
ferroportin. Consequently, ferroportin cannot be down regulated, leading to decreased 
ferritin inside the cells
37
. Humans have only one copy of the hepcidin gene (HAMP) but 
mice have duplication (Hamp 1 and Hamp 2). Hepcidin is present in mammals, reptiles, 
amphibians and fish with multiple hepcidins in the later species. In all species studied so 
far hepcidins conserve the eight cysteines and invariant glycine residues. Murine hepcidin 
2 cannot bind ferroportin because of a change T61I in the second amino acid of the five 
important N-terminal ones
35
.   
Most hepcidins have an antimicrobial activity. They have a weak activity against 
some gram-positive bacteria (Bacillus megaterium, Micrococcus luteus, Bacillus subtilis, 
Staphylococcus carnosus), gram- negative bacteria (Nisseria cinera) and the yeast 
Sacharomyces cerevisiae. Hepcidin does not have activity against the gram-negative 
Escherichia coli B21 and Psedumonas fluorescens or the yeast Rhodotorula rubra
35
. 
Only some hepcidins can regulate iron. Hamp 1 is the iron regulator whereas Hamp 2 is 
not
35
. Elevated synthesis of hepcidin hormone induced by ongoing blood stage parasites  








1.5.1  Transcriptional regulation of hepcidin 
Hepcidin production is regulated at transcription not at secretion
35
. Hepcidin is 
upregulated by IL-6, IL-1alpha and IL-1beta with inflammation. The transcription is 
mediated by the binding of STAT3 to the hepcidin promoter
35
.  Hemojuvelin is a surface 
protein associated with increased hepcidin expression
38
. This protein exists as a cleaved 
(cleavage between amino acids D165 and P166) or uncleaved form
39
. Hemojuvelin acts 
as a co receptor for bone morphogenetic protein (BMP) to enhance signaling
40
. A 
working model on mouse indicated that iron-induced BMP6 binds to hemojuvelin and to 
type I and II BMP receptors
41
. Type II BMP receptor phosphorylates and activates type I 
BMP receptor. Activated type I phosphorylates SMADs 1, 5 and 8 which along with 
SMAD 4 translocate to the nucleus to induce hepcidin expression. There are 4 types of I 
BMP receptors: Alk1, Alk2, Alk3 and Alk6. It was characterized on mice that Alk3 is 
required for basal expression of hepcidin whereas Alk2 and Alk3 (both present in the 
hepatocytes) are required for hepcidin expression as a response to iron and BMP 
signaling
42
. Mouse studies also revealed that BMP2 and BMP4 can bind to hemojuvelin 
and interact with BMP type I receptors Alk3 and Alk6 to activate SMAD1 to finally 
induce hepcidin transcription
38
. BMP7 and BMP9 can also induce expression of hepcidin 








1.5.2  Iron 
Studies of short-term or chronic iron supplementation in vivo reported a ten fold 
increase in hepcidin synthesis
44
 whereas a phlebotomy (inducing iron deficiency anemia) 
showed a decrease in transcription
45
. Holotransferrin inhibits the release of soluble 
hemojuvelin, leading to an enhanced response to BMP mediated by membrane-bound 
hemojuvelin
35
. In response to transferrin saturation, there is an increase in hemojuvelin 
sensitivity to cleavage and sensing by HFE (adult hemochromatosis gene product) and 
TFR2 (transferrin receptor 2 gene product) in hepatocytes
46
. Diferric transferrin re-
compartmentalizes TFR2 from lysosomes to recycling vesicles. HFE increases TFR2 
levels independently of diferric transferrin and consequently would indirectly regulate 
hepcidin synthesis
47
.   
 
1.5.3  Anemia and erythropoietic drive 
Anemia can affect hepcidin expression through tissue hypoxia, erythropoietin or 
increased erythropoiesis
35
. Erythropoiesis is associated with increased concentrations of 
erythropoietin and soluble transferrin receptor and inversely associated with hepcidin 
synthesis
48
. The hepcidin regulation mediated by anemia and erythropoietic drive is 
probably independent of the regulation by iron
49
. Animal studies and hepatoma cell lines 
have shown that when made hypoxic they have reduced levels of hepcidin. There is a 
relationship between oxygen transport, erythropoiesis, iron metabolism and the 
physiology of hypoxic response and iron availability
50
.  Hypoxia can induce the 
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expression of furin to cleave hemojuvelin
51
.Hypoxia can also upregulate directly 
HIF1alpha (hypoxia-inducible factor 1, alpha subunit) expression in hepatocytes
52
 and 
HIF1alpha inhibits stimulation of hepcidin expression by IL-6. A mutated form of the 




In summary, hepcidin is capable of integrating signals from iron in the circulation 




1. 6  Hepcidin, anemia and malaria 
Anemia can be produced during malaria because of hemolysis, sequestration and 
increased phagocytosis of both infected and uninfected erythrocytes, inability to 
counteract erythrocyte loss with erythropoiesis and dyserythropoiesis. Hemozoin and 
cytokines can inhibit erythropoietin response leading to unsuppressed hepcidin 
synthesis
54
. Unsuppressed hepcidin in turn increases dyserythropoiesis by iron 
sequestration in macrophages
55
. In malaria, there is a vicious cycle where loss of red 
blood cells leads to increased hepcidin and insufficient iron to support erythrocyte 
production. From another perspective, hepcidin could work as an innate immune 
regulator controlling parasitemia. Pathogens need iron for growth and have different 
preferences for certain types of cells
56
. For example, Plasmodium has hepatic and 
erythrocytic life cycle whereas Mycobacterium tuberculosis resides in macrophages. 





Both the erythrocytic and hepatic stages of Plasmodium need iron. Decreased 
levels of hepcidin can cause accumulation of iron in hepatocytes but high levels of the 
hormone can increase iron deposition in the reticuloendothelial system and reduce iron 
levels in the liver
57
. Studies showed that a current blood stage infection can trigger 
protection from a secondary or a superinfection with Plasmodium by iron redistribution: 
more iron in the spleen than in hepatocytes. In parallel blood stage infection could induce 
increased hepcidin levels in the liver of infected mice
9
. Hepcidin would restrict iron for 
parasite growth at liver stage infection. The interaction of hepcidin – iron – parasite 
suggests that iron deficiency could protect from malaria whereas iron supplementation 
could worsen the condition
33
.       
 
1.7  Drugs and therapy 
Until an effective vaccine is released to market, drug treatment of malaria is still 
the main strategy to decrease the burden of the disease. The problem of resistance 
emergence for the common drug treatments compromises their success. Antimalarial 
drugs can inhibit specific molecular gene targets such as the antifolates or atovaquone 
targeting dihydrofolate reductase or the cytochrome bc1 complex, respectively, or can 
target non-mutable metabolites like the quinolines inhibition of heme crystal formation or 
they generate parasite toxic compounds once activated by iron or heme such as the 




1.7.1  Antimalarial drugs inhibiting molecular targets 
1.7.1.1 Inhibiting mitochondrial cytochrome b 
Cytochrome b is part of the cytochrome bc1 complex (complex III) and a main 
component of the mitochondrial electron transport chain (ETC). The bc1 complex is 
involved in the pyrimidine biosynthesis and its inhibition kills the parasite
58
. In this 
category we find atovaquone
59
 used in combination with proguanil (called Malarone), 




 and the clinical 
candidate ELQ-300
62
, both with similar lipohilic side chains. Two novel quinolines: SL-
2-25 and SL-2-64 have dual activity against the cytochrome bc1 and the PfNDH2 (type II 
NADH dehydrogenase)
63
. The decoquinate containing quinoline (anticoccidial) has 
shown a potent in vitro antiplasmodial activity
64
. Also, new acridinediones (WR249685 
and floxacrine) and tetracyclic benzothiazepines have been reported
65
.   
 
1.7.1.2 Inhibitors of Plasmodium DHODH 
Plasmodium needs to synthesize pyrimidines de novo. Pyrimidines are precursors 
for DNA (thymine and cytosine), RNA (uracil and cytosine), glycoprotein and 
phospholipid biosynthesis. The flavoenzyme L-dihydro-orotate dehydrogenase 
(DHODH) is found in the matrix of mitochondria and catalyzes de conversion of L-
dihydroorotate to orotate and constitutes the limiting step for the biosynthesis pathway. 
DHOH uses the mitochondrial ubiquinone as final electron acceptor
66
.  Drugs that inhibit 





. The thiophene compound Genz-669178 reported a moderate oral 
bioavailability in rats and dogs, and good activity in vivo in P. berghei and P. falciparum 
models
63
.     
 
1.7.1.3 Inhibitors of the Plasmodium folate biosynthesis pathway 
Inhibition of folate synthesis and tetrahydrofolic acid recycling is effective for 
antimalarial treatment and prophylaxis. Dihydrofolate reductase (DHFR) is a key enzyme 
for folate biosynthesis and catalyzes the conversion of dihydrofolate to tetrahydrofolate. 
In the case of P. falciparum the enzyme also has a thymidylate synthase activity
68
. 
Pyrimethamine and cycloguanil are inhibitors of DHFR. A combination of sulphadoxine, 
inhibitor of the dihydropteroate synthase (DHPS, necessary for folate biosynthesis) and 
pyrimethamine  is used as an antimalarial
69
. Clinical isolates have shown quadruple 
mutations in the DHFR that lead to resistance to pyrimethamine
70,71,72
.  New compounds 
WR99210 and its prodrug PS-15 are active against the mutants. A substitution in the 
phenyl ring of PS-15 led to JPC-2056 maintaining the antimalarial activity
63
. P-218 is a 
new compound effective against wildtype and quadruple mutants and has lower toxicity 




1.7.1.4 Inhibitors of the non-mevalonate isoprenoid biosynthesis pathway 
The 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DOXPR) is involved the 
non-mevalonate pathway isoprenoid biosynthesis
74
. An inhibitor is fosmidomycin which 
20 
 
also functions as an antibacterial agent. The compound inhibits the formation of 
isoprenoids in the apicoplast targeting the isopentenyl diphospahte (IPP) biosynthesis. 
This target pathway is selective since humans obtain isoprenoids from the mevalonate 
pathway
63
. FR-9000098 is an analogue of fosmidomycin and is more active against P. 
falciparum. Fosmidomycin, in combination with clindamicycin (antimalarial), showed 
modest efficacy and safety in uncomplicated malaria in adults and children
75
.   
 
1.7.2  Antimalarial drugs with a complex mode of action 
1.7.2.1 Interfering with disposition of hemoglobin heme metabolism 
Heme is a metabolite target that does not mutate and is used by the quinoline drug 
class. The first antimalarial drug reported was quinine and then in 1940s
76
 was replaced 
by more effective synthetic drugs, chloroquine (CQ) the most important
77
.  CQ has 
excellent efficacy and low cost but nowadays faces widespread resistance
78
. Quinine and 
CQ interfere with the digestion process of hemoglobin during the intraerythrocytic 
development of Plasmodium. Specifically they prevent the formation of non-toxic 
hemozoin crystals by binding to growing faces of heme crystals to uncouple heme dimer 
incorporation into crystals
79
. Analogs of CQ with modifications to the alkyl side chain, 
can incorporate quinoline cores and can introduce aromatic groups in the amine located 
in the side chain
80
.  New compounds have been derived to circumvent the CQ resistance 
strains: pyronaridine, naphtoquine and ferroquine
63
. Amino-alcohols can also interfere 





halofantrine. Lumefantrine, while not a true quinoline is used in combination with 
artemisinin (Coartem). 
 
1.7.2.2 Endoperoxides cause various effects in Plasmodium 
Artemisinin is considered a prodrug activated by ferrous iron present in heme or 
bioavailable iron after hemoglobin catabolism by the parasite after erythrocyte invasion
82
. 
Iron chelation interferes with its activation and subsequent parasiticidal action. Some 
derivatives of artemisinins include: artemether, arteether and the carboxy-containing 
analogues artenilate and artesunate.  Dihydroartemisinin (sesquiterpene lactone) is the 
active metabolite of the various artemisinins and its exact mechanism of killing is still 
unknown. However, it is considered to have multiple targets because of its endoperoxide 
functionality which translates to slow acquisition of resistance
63
. Recent cases are being 
reported of a delayed parasite clearance in patients
83
. Artemisinin has the highest killing 
rates in vitro and in vivo and a favorable safety profile. During the erythrocyte stages the 
artemisinins have a broadest time dependence of action, longer than the quinolines
84
. In 
combination with other malaria drugs (artemisinin combination therapy - ACT) they have 
superior clinical efficacy.  The gametocytocidal activity impacts transmission in addition 
to clinical cure as well
85
. The most widely used is artemether, given in combination with 
lumefantrine (Coartem)
63
. Other derivatives with a better pharmacokinetics is the 10-
(alkylamino)-ART series such as artemisone and the ozonides (1,2,4-trioxolanes)
86
. From 
the ozonides, arterolane (OZ-277) and OZ-439 are in clinical trials
87
.        
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1.8  Resistance to antimalarial drugs 
Chloroquine, sulfadoxine/pyrimethamine (SP) and artemisinins are part of the 
first line treatment for their efficacy at killing P. falciparum infected red blood cells and 
for tolerability
88
.  The introduction of CQ as part of the therapy saved many lives in the 
early 50’s especially, however the emergence of CQ resistant strains from Southeast Asia 
to Africa complicated any effort for eradication and cure
89
. Although CQ was replaced by 
sulfadoxine/pyrimethamine, resistant strains to these antifolates became widespread. 
Also, artemisinins important in the treatment of uncomplicated and severe malaria are 






Drug resistance can be produced by de novo Plasmodium mutations selected 
through drug use in one person and by the transfer of the resistant alleles via mosquito 
transmission to others
91
. Phenotypic changes (one or multiple) can be produced by single 
point mutations, modifications in various loci or gene duplication
84
.  Compared to 
atovaquone and pyrimethamine (alone) the rate of de novo mutations with the quinolines 
or artemisinins leading to resistance is low.  
General mechanisms of drug resistance include: decrease in the active or passive 
uptake of the drug, conversion of drug to inactive metabolites, increasing the expression 
of the target or alterations in the enzyme target
91
. Plasmodium parasites lack the ability to 
degrade or enzymatically inactivate drugs. In Plasmodium drug targets like cytochrome 
b/c, DHFR or DHODH are subjected to resistance associated mutations. The quinoline 
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drug concentrations are decreased by import/export modulations without altering the drug 
target. Importantly, Plasmodium resistance to iron chelation has not been shown.  
 
1. 9.  Iron chelators as antimalarial drugs  
Many of the iron chelators proven to inhibit parasite growth in vitro are natural 
siderophores
25
. Important physical properties of iron chelators are: the 
hydrophilicity/hydrophobicity balance
92
, the affinity for the iron
92
, the selectivity for iron 
against other cations
93
, the selectivity for iron (III) against iron (II)
94
 and the number of 
coordination sites, being hexadentated chelators better to form stable complexes
25
. The 
major mechanisms of action include: withholding of iron necessary for metabolism such 
as replication
95
 and forming toxic complexes with iron that once inside the infected cell 
that produce free radical - mediated reactions
96
. Chelators are effective in vitro and in 
vivo, in erythrocytic and liver stages
25
. Potential target enzymes of iron chelator are: a) 
ribonucleotide reductase for individual nucleotide synthesis, chelation would limit the 
rate of DNA synthesis
97
 and therefore the reproduction of the parasite in the intra-
erythrocytic stage, especially at the trophozoite stage (characterized by the highest rates 
of metabolism and growth)
98
and b) gamma-aminolevulinate synthase or ferrochelatase, 
which are enzymes for de novo heme synthesis in the parasite. Heme acts as a prosthetic 
group on cytochromes that are necessary for electron transport and mitochondrial 
respiration and therefore survival of the parasite
25
. Inhibition of heme synthesis by iron 
chelators could disrupt the electron transport system.  
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1.9.1  Specific antimalarial iron chelators 
1.9.1.1 Desferrioxamine (DFO) 
DFO is the only iron chelator in clinical use in most countries. DFO is a 
trihydroxamic acid derived from Streptomyces pilosus and it is a hexandentate chelator 
that complexes iron 1:1. The drug has to be given parentally and continuously
99
. DFO has 
been included in chelation therapies for patients with iron-loading anemia. DFO is 
cytocidal and specific for late trophozoites and early schizonts
100
. A multi center study in 
Zambia showed an increased mortality of children with cerebral malaria when they 
received quinine in combination with DFO
101
. Higher mortality was significantly 
associated with hepatomegaly and slower clearance of parasites and fever whereas lower 
mortality with splenomegaly and faster clearance and fever. The study could not prove a 
beneficial effect on mortality in children with cerebral malaria when they received 




1.9.1.2 N-terminal derivatives of desferroxamine 
DFO alone is poorly permeable into parasitized cells but the N-derivatives with a 
hydrophobic moiety to DFO shows improved permeability
94
. The most hydrophobic 
derivative, methylanthranilic-DFO reduces parasite growth with an IC50 around 4 µM 






1.9.1.3 Reversed siderophores 
They represent another modified version of hydroxamate-based chelators such 
DFO. They are synthetic hydrophobic ferrichrome siderophores
102
. These chelators 
inhibit all stages of parasite. In vitro they are cytotoxic on rings and cytostatic on 
trophozoites
103
.   
 
1.9.1.4 Hydroxipyridinones 
They are neutral bidentate with high specificity for Fe (III). They are given orally 
to treat iron overload cases
104
. In vitro they inhibit P. falciparum growth in a dose-
dependent manner.  The representative compound of this group is called deferiprone (L1) 
and inhibits more than 50% of parasite growth when the drug is applied from 5 to 100µM 
continuously
95






They include SIH and 2-hydroxy-1-naphthylaldehyde m-fluorobenzoyl hydrazone 
(HNFBH) and are effective against all stages of parasite development with an IC50 
around 24 µM and 0.21 µM respectively. They show a dose-dependent response when 







They include ethane-1,2-bis(N-1-amino-3-ethylbutyl-3-thiol) (BAT) and 
N’,N’,N’-tris (2-methyl-2-mercaptopropyl)1,4,7-triazacyclononane (TAT). Their IC50 
around 7.6 for BAT and around 3.3 for TAT. They are cytotoxic to parasites especially 
for trophozoites and schizonts
107
.  
Plasmodium has an absolute requirement for iron and a lack of receptors for iron 
protein-carriers. This is a key vulnerability to be exploited as a drug target. The problem 
of increasing resistance of the parasites to current antimalarial drugs has posed the need 
to develop new mechanisms of antimalarial drug action which are also efficacious, safe 
and not prone to resistance. Iron chelation represents a new drug target to affect multiple 
stages of the life cycle of parasite. Iron chelation has the advantages of being a non-
mutable target like enzyme targets and it avoids the problem of targeting a specific 
structure for activity such in the cases of hemoglobinases. 
 
1.10  FBS0701 
1.10.1 Structure 
FBS0701 is a chemical analogue to bacterial siderophore desazadesferrithiocin
108
. 
FBS0701 is tridentate iron chelator (Figure 1.4). Like other siderophores, FBS0701 binds 













Figure 1.4. Chemical structure of FBS0701 or (S)3-(HO)-desazadesferrithiocin-polyether [DADFT-
















In normal human volunteers and in iron overload patients orally dosed with 3-40 
mg/Kg of FBS0701, the pharmacokinetics across the dosing range shows high 
bioavailability (>60%), dose-proportionality and a terminal t1/2 averaging 20 hours 
making once daily dosing feasible
110
. The addition of the polyether sidechain eliminated 
nephrotoxicity
110
. The Cmax averaged 170 µM with an AUC0-24h of 385 µM.hour/L at the 




































FBS0701 was well tolerated during a 7 day human dosing period with no dose-
dependent adverse events and no serious adverse events related to the drug
110
.  In another 




Based on these promising pharmacokinetic and safety data, 3 to 5 day 32 mg/kg 
course of treatment should be sufficient to clear parasites by maintaining mean plasma 
concentrations of FBS0701 well above the IC50 over 72-120 hour period
110
. The amount 
of iron excreted over this anticipated treatment period for malaria would not exceed 90-





1.11 Iron interventions 
One of the more recent controversial types of iron intervention is iron 
supplementation in malaria endemic areas. The iron supplementation policy of anemic 
individuals has been strongly debated since the study on Pemba Island that was 
hyperendemic for malaria. The study showed that iron and folate supplementation 
increase risk for hospitalization and death attributed (but not proven by a laboratory 
diagnosis) to be from malaria in iron replete but not in iron deficient children regardless 
of anemia
112
. From this study, programs on iron supplementation in malaria endemic 
areas were halted and also led medical health workers to reconsider the approach of iron 
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supplementation by screening out children who are iron-replete or combining 
supplementation with control strategies for the disease such as antimalarial treatment.  
In general, iron intervention strategies are based on the target population, the local 
health care and/or industry infrastructure available and local dietary and cultural habits 
and costs. The supply of iron amount is dependent on the iron requirements of the 
population and if their intention is to treat or prevent iron deficiency
16
. There are four 
main types of intervention: 
 
1.11.1  Dietary diversification 
This strategy increases the bioavailability of iron of traditional food or the 
consumption of food rich in iron. 
 
1.11.1.1 Bioavailability of iron  
1.11.1.1.1 Direct manipulation of food 
The processing of food and the techniques used for preparation could increase 
iron bioavailability of foods. Fermentation can reduce 90% of phytate that chelates iron, 
germination between 50-64% and soaking from 47-98%
113
. The type of strategy alone is 





1.11.1.1.2 Indirect manipulation of food 
It is especially used in developing countries to reduce iron deficiency. A strategy 
is cooking in iron pots that can increase iron available for absorption but can also cause 
iron overload
114
. Also, there are not studies about the impact on malaria.       
 
1.11.1.2 Foods rich in iron 
Iron content is very high in animal foods such pork, poultry, beef and fish and in 
special organs like liver. Unfortunately, poor women who are at higher risk of iron 




1.11.2 Food fortification 
It is referred to adding iron to food deliberately. Iron concentrations taken daily 
by fortification is less than taken by supplement.  
Organoleptic characteristics of iron make it hard to add the nutrient to foods. 
Ferrous sulfate is efficacious in fortified foods and is accepted by the WHO
115
. Ferrous 
fumarate lacks of studies to support its efficacy
16
. NAFeEDTA has proven effective in 
studies improving iron status in women and children. Other alternatives as ferric 
pyrophosphate and electrolytic iron are more expensive.       
Some methods of fortification are:  
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 Centrally fortified foods: distribute iron on staple foods, beverages or condiments.  
 Home fortification: implies adding iron directly to meals when eating. This is 
mainly used for treatment than prevention. 
 Biofortification: is a future strategy where iron concentration of staple food is 




1.11.3 Iron supplementation 
It is the most common method to treat anemia and iron deficiency. It consists on 
the oral delivery of iron in the form of a pill or liquid without the intervention of food. It 
is safe, efficacious and less expensive. Programs with iron supplementation have proven 
to be effective at prevention of iron-deficient anemia
116
. The side effects of iron 
supplementation are nausea, diarrhea or constipation, anorexia and dizziness. A study in 
Gambia showed that using between 0.5 mg and 1.5 mg of folic acid along with oral iron 
(47 mg) there was not interference with sulfadoxine - pyrimethamine in pregnant 
women
117
.     
Based on the statement that iron supplementation increases susceptibility to 
malaria, then the opposite, meaning iron-deficient and/or anemic people could have less 
risk to malaria. Studies have shown contradictory observations at testing this idea. Two 
often cited older human studies associated injectable iron or oral refeeding in famine 
stricken refugees with high percentage of symptomatic malaria
118,119
. Other studies, 





. However, iron supplementation policy has been debated because of a 
study done in Pemba (hyperendemic for malaria)
112
. The study showed that iron and 
folate supplementation increase the risk for hospitalization and death from malaria in iron 
replete rather that iron deficient children regardless of anemia. Oral iron (12.5 mg) and 
folate (50 µg) had a protective effect on disease in children who were both iron deficient 
and anemic; no effect in children iron deficient and with no anemia, but had a significant 
risk of adverse outcomes measured in hospital admissions and deaths  in children iron 
replete with or without anemia
112
.   
 
1.11.4 Non-dietary interventions 
It is based on delaying the cord clamping by 2 – 3 minutes to have a higher 
transfusion of placental blood to the baby. The baby can a have a total increase in iron 
content at birth preventing iron deficiency during his/her 1st year. There is not specific 
safety and efficacy data about this method in malaria endemic areas
16
.     
 
1.12 Thesis overview and objectives  
The broad goal of the project was to better understand the importance of iron 
compartmentalization and bioavailability of the host on Plasmodium development. The 
world faces increasing resistance of parasites to current antimalarial drugs that create a 
need to develop new drugs with novel mechanisms of action efficacious, safe and not 
prone to resistance. Considering iron as a non mutable target, we studied the 
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consequences of iron chelation on the blood, liver and mosquito stages of the parasite life 
cycle. We tested a new iron chelator known as FBS070 in vitro and in vivo mouse model.   
The problem of geographical overlap between iron deficiency anemia and malaria 
brings controversy on how effective iron supplementation interventions are to treat 
anemia in malaria endemic areas. In this research, we evaluated the type and timing of 
iron diet during iron repletion on hepatic parasite load. On parallel, we studied the 
importance of the iron regulatory hormone hepcidin on infection and its interplay with 
the iron diets. Also, we studied liver stage infection on genotypic anemic mice receiving 
exogenous hepcidin and confirmed the importance of the hormone and the consequent 
compartmentalization of iron it induces.  
Aims: 
Aim 1. To characterize the antimalarial pharmacodynamics of the novel iron 
chelator FBS0701.  
We hypothesize that FBS0701 can function as an antimalarial drug that targets the 
hepatic, erythrocytic and mosquito stages.  
Specific aim 1.1: To identify the FBS0701 effective dose, timing and duration of 
antimalarial action in vivo and the IC50 and mechanism of action in vitro. 
Specific aim 1.2: To characterize the interaction of FBS0701 with other 
antimalarials on blood and hepatic stages in vitro and in vivo. 
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Specific aim 1.3: To test the activity of FBS0701on mosquito stages previous 
treatment of P. falciparum gametocytes. 
Aim 2.  To evaluate the effect of the type and timing of iron diet on murine malaria 
infection during iron repletion with implications for human nutritional iron 
supplementation in malaria endemic areas.   
We hypothesize that bioavailable iron for the parasite influences the hepatic stage 
significantly more. The type or timing of iron supplementation during iron replenishment 
will alter malaria outcome dependent on an iron compartmentalization effect.  
Specific aim 2.1: To compare the effect of a low, normal and high iron diet given 
for two weeks versus six weeks on hepatic malaria infection in iron replete mice and iron 
deficient mice. 
Specific aim 2.2: To evaluate the level of hepatic malaria infection on transgenic 
overexpressing hepcidin (Tg+) mice upon the addition of exogenous hepcidin and on 
hemoglobin deficient mice (hbd).  
Specific aim 2.3: To correlate malaria hepatic outcomes with the level of the iron 
regulatory hormone hepcidin in transgenic anemic mice, anemic wild type inbred mice 














ANTIMALARIAL IRON CHELATOR, FBS0701, SHOWS ASEXUAL AND 
GAMETOCYTE PLASMODIUM FALCIPARUM ACTIVITY AND SINGLE 










2.1  ABSTRACT 
Iron chelators for the treatment of malaria have proven therapeutic activity in 
vitro and in vivo in both humans and mice, but their clinical use is limited by the 
unsuitable absorption and pharmacokinetic properties of the few available iron chelators. 
FBS0701, (S)3’’-(HO)-desazadesferrithiocin-polyether [DADFT-PE], is an oral iron 
chelator currently in Phase 2 human studies for the treatment of transfusional iron 
overload. The drug has very favorable absorption and pharmacokinetic properties 
allowing for once-daily use to deplete circulating free iron with human plasma 
concentrations in the high µM range. Here we show that FBS0701 has inhibition 
concentration 50% (IC50 ) of 6 µM for Plasmodium falciparum in contrast to the IC50 for 
deferiprone and deferoxamine at 15 and 30 µM respectively. In combination, FBS0701 
interfered with artemisinin parasite inhibition and was additive with chloroquine or 
quinine parasite inhibition. FBS0701 killed early stage P. falciparum gametocytes. In the 
P. berghei Thompson suppression test, a single dose of 100 mg/kg reduced day three 
parasitemia and prolonged survival, but did not cure mice. Treatment with a single oral 
dose of 100 mg/kg one day after infection with 10 million lethal P. yoelii 17XL cured all 
the mice. Pretreatment of mice with a single oral dose of FBS0701 seven days or one day 
before resulted in the cure of some mice. Plasma exposures and other pharmacokinetics 
parameters in mice of the 100 mg/kg dose are similar to a 3 mg/kg dose in humans. In 
conclusion, FBS0701 demonstrates a single oral dose cure of the lethal P. yoelii model. 
Significantly, this effect persists after the chelator has cleared from plasma. FBS0701 was 
demonstrated to remove labile iron from erythrocytes as well as enter erythrocytes to 
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chelate iron. FBS0701 may find clinically utility as monotherapy, a malarial prophylactic 
or, more likely, in combination with other antimalarials.  
 
2.2  INTRODUCTION 
Iron metabolism is a proven target for many malaria drugs. The quinolines like 
chloroquine and quinine interfere with iron protoporphyrin IX crystallization in the 
digestive vacuole
121
. The artemisinins are activated by iron to generate carbon-centered 
radicals that rapidly kill parasites
122
. Iron chelators have been explored as alternative 
malaria drugs for decades
25
. Intravenous deferoxamine does increase clearance of 
parasites
123
 but in an important clinical trial deferoxamine did not affect outcome from 
severe cerebral malaria
124
. The orally available deferiprone was also suboptimum in an 
uncomplicated malaria trial because of poor iron clearance after oral absorption
105
. Iron 
regulation is potent in limiting liver stage multiplication mediated, in part, by hepcidin 
pathway
9
. Iron supplementation increases hepatic parasites
125
 and iron chelators decrease 
hepatic parasites
9
. For intraerythrocyte Plasmodium, the literature describes chelation of 
both labile iron pools in parasites as well as infected erythrocyte cytosol. Deferoxamine 
decreases available iron in the nucleus and parasite cytosol. The exact mechanism of 
parasite killing is not known but evidence points to a iron chelator mechanism of limiting 
iron for ribonucleotide reductase production of nucleotides, however earlier studies also 
suggest a toxic mechanism of erythrocytic Plasmodium killing
25
. A drawback for 






The potent novel chemical analogue of the bacterial siderophore desferrithiocin is 
entering clinical trials for transfusional iron overload. (S)-4,5-dihydro-2-[2-hydroxy-3-
(3,6,9-triox-adecyloxy)phenyl]4-methyl-4-thiazolecarboxylic acid also known as 
(S)3’’-(HO)-desazadesferrithiocin-polyether [DADFT-PE] or more simply as FBS0701 





. The molecular weight of the formulated salt is 441 while free base is 400. The 
iron clearing efficiency in rodents is 10.6 ± 4.4% and in primates is 23 ± 4.1%
109,128
. In 
contrast the iron clearing efficiency for deferoxamine is 2.8% and 5.5% and deferiprone 
is 1.2% and 2.1% in rodents and monkeys, respectively. In normal human volunteers 
dosed with FBS0701 with 6, 10 or 16 mg/kg, the pharmacokinetics across the dosing 
range indicates high bioavailability Cmax of 22.7, 41.5 and 87.0 µM respectively, dose-
proportionality and a terminal t1/2 permitting once-daily dosing
110
. Here we investigated 
the actions of this iron chelator on P. falciparum blood stage parasites, its action against 
gametocytes and efficacy in murine malaria models.  
 
2.3  Methods  
2.3.1  Materials 
FBS0701 was obtained from Aptuit (Kansas City) LLC under good 
manufacturing practice. All other reagents and chemicals are from Sigma unless 






2.3.2  P. falciparum culture  
Direct effect of FBS7010 on P. falciparum was determined by SYBR green I 
(Invitrogen-Molecular Probes, Eugene OR) based assay as described earlier
129
. Briefly, 
the inhibition assay was initiated by adding serially diluted FBS7010 in 96 well 
microplates followed by sorbitol synchronized 1% ring stage parasites at 1% hematocrit 
in RPMI 1640 media with glutamine and HEPES supplemented with 10% human serum 
and 50 mg/ml hypoxanthine. Culture plates were then transferred to 37ºC incubator and 
maintained in the environment of 5% O2, 5% CO2 and 90% N2 for 72 hrs. 2x SYBR 
Green I solution in lysis buffer was added after one cycle of freeze and thaw. Plates were 
then placed at room temperature in dark for 1–2 hours and fluorescence values were 
quantitated in a plate reader (HTS 7000, Perkin Elmer) at emission and excitation 
wavelengths of 535 and 485, respectively. For fractional inhibition analysis quinine, 
quinidine, chloroquine and artemisinin were used at concentrations ranging from 1 to 100 
nM and FBS0701 from 1–15 µM. The fractional inhibition was analyzed according to the 
original Elion and Hitchings paper
130
 with modifications by Bell
131
. The fraction of the 
chloroquine, quinine or artemisinin drug in combination with FBS0701 that produced an 
IC50 was divided by the IC50 of the chloroquine, quinine or artemisinin alone for the ratio 
on the y-axis. The x-axis was fraction of FBS0701 in combination with the chloroquine, 
quinine or artemisinin divided by concentration of FBS0701 which produced an IC50.  
To test the effect of FBS0701 on gametocyte stages, P. falciparum NF54 cultures 
were initiated in 24 well plates at 0.5% asexual parasitemia and 4% hematocrit
132
. 
Medium was changed daily up to day 18, without addition of fresh RBCs. Continuous 
cultivation without dilution leads to concomitant crash of asexual parasitemia and 
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induction of gamteocytogenesis by day 5. The gametocytemia was approximately 7% at 
start of treatment. FBS0701 was dosed in wells at Days 9–10, when majority of 
gametocytes were in early stage of development (Stage I, II) or Days 14–15 when 
majority of gametocytes have matured to stage III to V. Levels of gametocytemia were 
determined on day 18 and the mean number of gametocytes was calculated by counting 
10 high-powered (1000 x) fields from triplicate wells per condition. More than 1000 
erythrocytes were enumerated by random scanning across Giemsa blood film. 
 
2.3.3  Animal ethics 
All animal experiments were performed on protocol ‘‘Malaria Drug Testing in 
Mice’’ (Approval ID-MO09H401) approved by The Johns Hopkins Animal Care and Use 
Committee in accordance with institutional standards. 
 
2.3.4  Malaria murine drug testing 
Male 5–6 week old at approximately 25 ± 2 g C57/BL6 mice were purchased 
from Jackson Laboratories (Maine, USA). The P .berghei ANKA strain was obtained 
from ATCC; the P. yoelii 17x lethal strain was the gift of James Burns (Drexel 
University). Freshly made solutions of FBS0701 in water were used for all the 
experiments and drug was administered by oral cannulation at indicated times. Murine 
infection was initiated by intraperitoneal inoculation of 10 million infected red blood 
cells for P. berghei and 10 million for P. yoelii. Blood was taken from the tail vein for 
blood smears.  
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Parasitemias were determined in a blinded fashion by counting four fields of 
approximately 200 erythrocytes per field. Mice that survived for 30 days post infection 
with complete disappearance of parasitemia and no recrudescence within the next 30 days 
were considered cured.  
 
2.3.5  Pharmacokinetics 
30 female Balb/c mice were dosed with 100 mg/kg of FBS0701 by oral 
cannulation and blood was drawn by cardiac puncture during anesthesia. Whole blood 
was separated into plasma and erythrocytes and plasma was sent for analysis by Covance 




2.3.6  Measurement of bioavailable labile iron in erythrocytes 
Blood was collected from healthy subjects washed 2 times with PBS. 
Erythrocytes were then incubated with 0.125 µM calcein (Invitrogen) in PBS for 15 
minutes at 37ºC, washed 2 times with PBS and then allowed to rest for 10 minutes at 
37ºC in the dark
133,30,134
.  
Cells were incubated with PBS, 100 µM FBS0701 or 100 µM diferiprone for 1 
hour at 37ºC. Cells were analyzed by flow cytometry using a modified FACS-Calibur 
with 2 lasers 30 mW 488 Diode Pumped Solid State laser and a 25 mW 637 red diode 
laser (FACS-Calibur; Becton Dickinson, Mount View CA, modified by Cytek 
Development). Data was collected using FlowJo CE and analyzed using Summit v4.3.01. 
The emission of 400,000 cells was analyzed using logarithmic amplification for 
fluorescence signal height (FL-1, 530/30) and linear amplification for forward scatter 
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(FSC) and side scatter (SSC). The threshold was set at FSC to exclude cell debris and 
microparticles. The mean fluorescence intensity (MFI) was calculated using Summit 
v4.3.01. Individual experiments were performed in triplicate and also biologic duplicate 
with different human erythrocyte donors. The statistical significance was calculated using 
the Student’s t-test. 
 
2.4  RESULTS 
2.4.1  P. falciparum blood stage inhibition  
In the chloroquine and quinine sensitive isolate 3D7, the IC50 with continuous 
drug exposure was 6 µM (IC50=3 µM and IC90=10 µM). Morphologically the FBS0701 
exposed parasites were shrunken. Stage and concentration dependence of FBS0701 iron 
chelation showed that for continuous drug exposure starting at ring and trophozoite stage 
the IC50 was similar at 6 µM, but when drug exposure was initiated at schizont stage after 
DNA replication, the IC50 increased by almost three fold to 15–17 µM. Investigation of 
dose-dependent killing of gametocytes shows that 100 µM inhibited more than 90% of 
early stage I and II gametocytes but only about 40% of late stage III or IV gametocytes, 
10 µM FBS0701 had minimal 37% decrease in the number of gametocytes (Figure 2.1). 
Because of the known interactions of iron chelators with the artemisinins
126,131,135
, we 
investigated interaction in vitro with P. falciparum. Fractional inhibition indicates 
interference with artemisinin and an additive action with the quinolines like chloroquine 




















Figure 2.1. FBS0701 inhibits early stage not late stage gametocytes. Gametocyte cultures of P. 
falciparum NF54 strain were initiated at 0.5% asexual parasitemia and 4% hematocrit in 24 well culture 
plates. Gametocytes were morphologically determined by Giemsa stain and counted on Day 18 with no 
drug (A) or 100 µM FBS0701 dosed in wells at Days 9–10 (B) or Days 14–15 (C) post-culture initiation. 
Dose dependent inhibition is more pronounced with early gametocyte stage I and II (day 9–10 dosing) than 
gametocyte late stages III-IV (day 14–15 dosing) (D). Gametocytemia was approximately 7% at the start of 
treatment with FBS0701 on indicated days. Gametocytes per 10 high power fields (excess of 1000 
erythrocytes) in each of three replicate wells for each condition were counted on Day 18. Control wells had 
7.4% mean gametocytes. Data expressed as percent inhibition of control. Standard deviation of triplicate 















Figure 2.2. FBS0701 interferes with artemisinin but not the quinolines like chloroquine or quinine. 
Fractional inhibition curve for the quinolines and artemisinin with FBS0701. Up to 10 µM FBS0701 does 
not change the low nM IC50 of artemisinin (filled square). In contrast for the quinolines 1, 5, 7.5 and 10 µM 
FBS0701 reduced the IC50 in an additive manner for chloroquine (empty circle), quinine (empty triangle) or 
quinidine (filled triangle). For each axis the concentration of drug in combination which equals the 


















2.4.2  Murine malaria inhibition  
In the lethal P. berghei ANKA mouse model, FBS0701 showed a 50% reduction 
in day 5 parasitemia and delayed death by more than ten days at the 100 mg/kg dose, 
regardless of single day dosing for one day, three days or seven days (Figure 2.3). The 
lethal P. yoelii model was used next because while lethal infection results from invasion 
of both normocytes and reticulocytes, a recent vaccine study demonstrated that by largely 
restricting invasion to reticulocytes the infection was no longer lethal
136
.  
We dosed mice with a single oral dose of FBS0701either seven days or one day 
prior to parasite inoculation and also dosed a day after inoculation. All infected untreated 
control mice died by day 11. All the mice treated a day after infection with a single oral 
dose of the iron chelator survived (Figure 2.4). Surprisingly two to three mice with 
FBS0701 pretreatment one or seven days prior to intraperitoneal P. yoelii infection still 
lived suggesting a lingering effect after the drug was cleared. In this model we again saw 
a small reduction in day 3 parasitemia. In all surviving mice, which had been dosed with 
FBS0701, the day 16 parasitemia was near 50% but confined to reticulocytes rather than 
normocytes (Figure 2.5). Resolution of parasitemia coincided with return of reticulocyte 


























Figure 2.3. FBS0701 delays mouse death after infection with P. berghei. We performed a Thompson 
suppression test in the P. berghei mouse model. Mice in groups of five were inoculated with 10 million 
parasites intraperitoneally and were dose daily with 100 mg/ kg FBS0701 (200 µl) by oral gavage for 4 
consecutive days. Parasitemia was determined 5 days after infection by examining 20 fields of blood 
smears for each of the 5 mice.  FBS0701 induced 50% percent reduction in parasitemia and prolonged 
survival significantly. Five mg/Kg chloroquine dosed daily for 4 days was used as positive control for 
parasite death (A and B). Similarly to test the duration of dosing needed to suppress parasites, 100 mg/Kg 
FBS0701 was given orally daily for 3 days, 7 days and on  a single oral dose. The survival curves were 


























Figure 2.4. FBS0701 cures lethal P. yoelii in a single dose. Male mice in groups of 4 were inoculated 
with 10 million lethal P. yoelii parasites by IP injection on day 0. A single oral dose of FBS0701 at 100 
mg/kg was given on day -7, day -1 and day +1 relative to infection. The survival curve shows complete 
protection with day +1 dosing and significant protection in animals pre-treated day -7 and day -1. Treated 












Figure 2.5. Protection is associated with exclusion of infection from normocytes in P. yoelii infected 
mice. On day 3 blood films from control (A) and FBS0701 (B) treated male mice both show infection in 
normocytes. On day 16 P. yoelii infection is largely restricted to young reticulocytes with only a few in 
normocytes in mice treated on day -7 (C) or day -1 (D). Quantification of Giemsa-stained blood films (E) 
indicated that on day 3 infected normocytes (black bars) outnumbered by more than 20 fold infected 
reticulocytes (hatched bar). On day 16 most of the erythrocytes are either infected (hatched bars) or 
uninfected reticulocytes (clear bars). By day 23 more than 80 to 90% of the erythrocytes are uninfected 
normocytes. Parasitemia on day 3 is reduced compared to control animals which are absent in subsequent 
days due to control animal death. Quantification was performed on counting at least 500 erythrocytes per 
mouse and averaged in the groups of 4 or number of remaining mice. Counts are represented as number of 
infected or uninfected normocytes or reticulocytes out of 100. Error is standard deviation of means between 
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2.4.3  Mouse pharmacokinetics 
We performed a pharmacokinetic analysis of FBS0701 dosing in fed mice without 
malaria. One hundred mg/kg dosing resulted in 17 µM levels at one hour that by 8 hours 



































Figure 2.6. Pharmacokinetics of FBS0701 in mice show high peak values but below concentrations 
for humans. 21 fed mice were given single oral dose at 100 mg/kg (black squares) and were sacrificed at 
indicated time with whole blood separated into erythrocytes and plasma. At least 200 µl of plasma was 
analyzed for drug levels in the three mice at each time point. Error is standard deviation of the mean. The 
published data for FBS0701 kinetics in humans at doses of 6 mg/kg (blue triangle), 10 mg/kg (red triangle) 













2.4.4  Removal of labile erythrocyte iron 
Calcein has been used as an intracellular iron probe
137,138
. Labile iron bound to 
low molecular weight, low affinity chelators binds and quenches calcein to generate the 
baseline equilibrium fluorescent intensity. The labile iron pools in normal erythrocytes 
has been determined to be approximately 1 µM
133,30
. Similar to deferiprone, the iron 
chelator FBS0701 at 100 µM was able to enter erythrocytes as evidenced by the increase 
in fluorescent intensity consistent with the release of iron from calcein (Figure 2.7A and 
B). Incubation of the FBS0701 and deferiprone for either one or two hours showed no 
difference in endpoint fluorescence intensity. To measure the removal of intracellular 
iron by chelation, erythrocytes at 4 x 10
6 
cells/ml (0.125% hematocrit) were incubated for 
an hour with 100 µM of either deferiprone or FBS0701, washed and then placed in PBS 
overnight. Figure 2.7C shows that fluorescence in erythrocytes pre-treated with FBS0701 
increased slightly from a mean fluorescence intensity (MFI) of 17 to 20. Pretreatment 
with deferiprone showed a slight though statistically insignificant decrease in MFI. 
Addition of either iron chelators to cells previously incubated with FBS0701 
showed a small rise of approximately 5 MFI compared to an increase of approximately 
15 seen with either PBS or deferiprone-incubated cells demonstrating that in 


















Figure 2.7. FBS0701 treatment chelates intracellular erythrocytic iron to the same extent as 
deferiprone but unlike deferiprone, removes iron from erythrocytes. Aliquots 1–5 x10
6 
erythrocytes 
from two separate healthy donors were stained in the dark with 0.125 µM calcein-AM for 15 minutes at 
37ºC. Cells were washed twice with PBS and allowed to rest for 10 minutes at 37ºC in the dark. Flow 
cytometry on FACS-Calibur records fluorescent signal height of calcein on 40,000 cells. A. Calcein-AM 
fluorescence histograms of unstained (no calcein) erythrocytes (red) and calcein-stained erythrocytes 
followed by incubation without (green) or with iron chelator L1 (blue) or FBS0701(yellow) show an 
increase in fluorescent signal intensity with iron chelator indicating displacement of labile iron from 
calcein. The L1 and FBS0701 peaks overlap. B. Washed erythrocytes after calcein-AM staining were 
incubated with PBS (green hatched bars), 100 µM L1 (deferiprone) (red dotted bars) or 100 µM FBS0701 
(blue solid bars) chelator for 1 hr or 2 hr. Both chelators were able to enter erythrocyte and chelate iron 
once bound to calcein to increase MFI. C. Erythrocytes were incubated with PBS, 100 µM L1 (deferiprone) 
or 100 µM FBS7010 chelator for 1 hr and washed twice with PBS and incubated overnight in PBS. 
Erythrocytes were then washed, stained with calcein-AM and incubated with either L1 (red dotted bars) or 
FBS0701 (blue solid bars). The baseline calcein fluorescence in FBS0701 pre-treated cells was higher 
indicating a lower concentration of labile iron in these erythrocytes, while baseline MFI in cells incubated 
with deferiprone have is essentially unchanged. D. Change in Mean Fluorescent Intensity is shown for each 
of the conditions described in C. In the FBS0701 pre-treated cells, the addition of 100 µM of either chelator 
resulted in a change in MFI of 5 compared to a change of 15 in cells treated with either PBS or deferiprone. 
The data in B was performed in three replicates on RBCs from a single blood donor while C and D was 
performed using RBCs from two different donors each in triplicate and mean and standard deviation (SD) 
of the 6 data points is shown. Student’s t-test shows a statistical significant difference in the change in MFI 
for both iron chelators and PBS in B and C. In C, baseline FBS0701 MFI is higher than both PBS and 
deferiprone (p<0.05) and in D the change in MFI with FBS0701 after the overnight pre-treatment is less 






A bioavailable oral iron chelator is an attractive and proven objective as an 
antimalarial agent. Much of the lack of efficacy of previous iron chelators for malaria 
therapy can be attributed to pharmacokinetic limitations including bioavailability, poor 
iron clearance efficiency and short-half life. FBS0701 has high solubility and a log p of -
1.22 permitting good oral bioavailability and much better iron clearance than 
deferoxamine and deferiprone. Here we demonstrate activity against blood stage P. 
falciparum and also single dose cure in a lethal mouse malaria model. A potential 
limitation is the known interference to the artemisinin class of drugs. However, the 
evidence from this work indicates that FBS0701 may remove an irreplaceable source of 
iron in normocytes in mice. Previous studies on where iron is removed with 
deferoxamine in the calcein measurements showed a decrease in labile iron in both 
infected and uninfected erythrocytes. We have not demonstrated a decrease in nonheme 
iron in these studies but suggest that the effect we see in vivo is not from a new 
recompartmentalization of iron but from a decrease in erythrocyte levels. Consistent with 
other reports
126,131,135
, we have demonstrated in vitro interference when both iron 
chelators and artemisinin are present simultaneously, but have not tested whether pre-
treatment with FBS0701 before infection interferes with artemisinin activity. 
Interestingly, the dose of iron chelator largely restricted lethal P. yoelii to young 
erythrocytes even almost 28 days after the drug was dosed and three weeks into infection. 
Mouse erythrocytes have a life span of about 60 days
139,140
. Additional studies of the 
timing of iron chelator days to weeks before lethal P. yoelii infection will provide 
evidence to replenishment of this erythrocyte bioavailable source of iron for Plasmodium. 
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The mouse pharmacokinetic parameters are close to those obtained in the rat model
128
. 
Most of the iron-FBS0701 complex was excreted in the bile while free FBS0701 has 
renal excretion
128
. The relative level of FBS0701 in the rodent shows liver> kidney> 
plasma> pancreas> heart.  
Interestingly, humans show approximately ten times higher plasma concentrations 
compared to mouse for a given mg/kg dose. However, in studies comparing dose 
proportionality for cancer drugs where toxicity is a larger issue 100 mg/kg dose in mice 
represents a dose of 300 mg/m
2
 while a 10 mg/kg in humans is equivalent to 370 mg/m
2 
141
. The implications are that in humans, effective drug concentrations above minimal P. 
falciparum inhibition concentrations last less than ten hours. In the P. falciparum in vitro 
drug testing the drug is at continuous concentration for three days. In the mouse in vivo 
studies here we have demonstrated a persistent effect weeks after the drug was dosed.  
This data indicate that iron chelation is able to remove a bioavailable source 
which persists and plays a role in parasite inhibition. Unlike many of the long half-life 
blood stage active quinolines which rely on time above inhibition concentration to kill 
parasites, FBS0701 has an effect possibly by perturbing an iron compartment in the 
circulating erythrocytes. The determination of relative labile iron concentrations using 
calcein indicates FBS0701 is able to enter erythrocytes and bind iron bound to calcein.  
 
More importantly, in contrast to deferiprone, FBS0701 was able to remove labile 
iron from erythrocytes, an effect that persisted for at least 16 hours. This is the first study 
to demonstrate the egress of labile iron complexed with a chelator complex from 
erythrocytes. This has important clinical implications for the use of an iron chelator in the 
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treatment of malaria as well as the ability of FBS0701 to remove iron from other cell 
types.  
In the malaria iron chelator literature there is some debate whether iron chelators 
inhibit by limiting DNA replication which in many bacteria and mammalian cells is 
cytostatic or whether iron chelators are toxic and therefore parasiticidal to Plasmodium. 
Early stage gametocytes do not replicate DNA, so the data which show early stage 
inhibition with FBS0701 may indicate an additional toxic mechanism of inhibition at the 
high dose used in the gametocyte assay at the stages digesting the iron and hemoglobin 
rich erythrocyte cytoplasm. In summary, FBS0701 demonstrates more potent inhibition 
for P. falciparum than previous iron chelators in clinical use. The activity persists in mice 
after the drug is below inhibition concentrations of approximately 5 µM. Our gametocyte 
data suggest a combined toxic mechanism in presence of erythrocyte cytosol ingestion in 
addition to the proposed mechanism of limiting DNA synthesis. In the lethal P. yoelii 
murine malaria model we show single oral dose cure. The removal of erythrocytic iron 
from intracellular bioavailable pools likely contributes to both the antimalarial activity 
and duration of effect of FBS0701 accounting for these effects in the relative absence of 
drug in plasma. FBS0701 may find clinically utility as monotherapy, a malarial 
prophylactic or, more likely, in combination with other antimalarials after further 
preclinical testing to investigate liver stage activity, duration of blood stage interference 
with the artemisinins or possibly inhibition of transmission in mosquito stages ingesting 
























3.1  ABSTRACT 
Iron is necessary for Plasmodium development, during blood and hepatic stages. 
The coincidence of malaria and iron deficiency makes it more difficult to treat both 
conditions as iron supplementation can increase malaria disease and malaria disease 
decreases iron absorption. In fact, some studies and programs on iron supplementation 
had to be stopped because of an increase in malaria mortality rates.  
Here we confirmed the importance of iron by evaluating the effect of the new iron 
chelator FBS0701 on the murine malaria hepatic stage. FBS0701 reduced the parasite 
load and could also act in a synergistic manner with another antimalarial, primaquine. 
Also, we studied the differences on hepatic infection loads on transgenic anemic mice: 
overexpressing hepcidin with reduced iron stores in the liver and hemoglobin deficient 
mice with normal hepatic iron stores.  We found lower parasite numbers on mice 
chronically overexpressing hepcidin. The anemic mice with reported normal liver iron 
had no changes in liver parasite number. 
Finally, we studied the effect of low and high iron diets on the hepatic stage of 
murine malaria and the interplay of hepcidin with the hepatic infection levels. We used 
mice that were both anemic and iron deficient by ZnPPIX levels as well as non-anemic, 
iron replete mice and gave both groups low and high iron diets for 2 and 6 weeks. Our 
results showed that high iron diets increased liver stage parasites in non-anemic mice and 
that iron supplementation predominated over a negative hepcidin effect. With our 
research we partially replicated in mice the human findings from the Pemba study. We 
began to see the increase in liver stage parasite numbers after 2 weeks which became 
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more significant after 6 weeks of the high iron diet. While the liver stages are 
asymptomatic, increasing the number of Plasmodium liver stages may synergize with 
blood stage increases after iron supplementation to increase malaria morbidity and 
mortality. 
 
3.2  INTRODUCTION 
Each year approximately 500 million cases of human malaria occur, with most 
morbidity and mortality in children under five in SubSaharan Africa
142
. Malaria infection 
coincides geographically with iron deficiency anemia. Malaria contributes to anemia by 
decreasing intestinal iron absorption, restricting erythropoiesis and sequestering 
bioavailable iron in ferritin stores
6
.  Prevalence of anemia can be as high as 95% in 
malaria highly endemic areas like Pemba
143
. Studies examining malaria and anemia have 
resulted in contradictory findings. Some older studies associated injectable iron or oral 
refeeding in famine stricken refugees with a high percentage of symptomatic 
malaria
118,119
. However, other studies including a meta-analysis did not show 
exacerbation of human malaria with oral iron replacement
120,144,143,145,146
. Policy on iron 
supplementation of anemic individuals has been intensely debated after the study in the 
Island of Pemba, hyperendemic for malaria. Results of this study showed that both iron 
and folate supplementation together increased the risk for hospitalization and death 
presumed to be from malaria in iron replete rather than iron deficient children regardless 
of anemia
112
.  The supplementation had a protective effect in children who were both iron 
deficient (elevated ZnPPIX as a metric) and anemic; no effect in children iron deficient 
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and with no anemia, but an apparent significant risk of adverse outcomes and deaths in 
children iron replete with or without anemia.  
Iron is important for most living organisms including Plasmodium species. Iron 
supplementation increases hepatic parasite number and iron chelators decrease the 
development of these exoerythrocytic forms 
9
.  The level of hepcidin, an important iron 
regulator, is increased in blood stage malaria. Hepcidin limits liver stage infection levels
9
 
and induces ferroportin degradation. Without ferroportin, iron absorption is limited from 
intestinal cells and so does its release from recycling macrophages during malaria 
34,147,148
. Hepcidin is also induced by inflammation 
56,149
 and down-regulated by hypoxia 
or iron deficiency
150
.  The biologic mechanisms and timing affecting iron 
supplementation as well as the interplay of hepcidin and iron supplementation over time 
has not been defined in the context of iron-deficiency anemia and liver stage malaria.  
In the present study, we tested the effect of the new iron chelator FBS0701 on the 
liver stage as well as two different genotypic mice with predicted low and normal iron 
stores.  We also used anemic iron-deficient and non-anemic iron-replete mice to compare 
the effect of high, normal and low iron diets and timing of the iron supplementation on 







3.3  Methods 
3.3.1   Materials 
Special mouse chow was ordered from (Harlan, Madison, WI).  Low iron diet 
(TD.99397) had 2-6 mg iron/kg, normal iron diet (TD.08713) had 200 mg iron/kg and 
high iron diet (TD.08714) had 20 g iron/kg.  FBS0701 produced under good 
manufacturing practice was obtained from Aptuit (Kansas City) LLC.  
 
3.3.2 Animal care  
Five month old female Balb/c mice were purchased from Jackson Laboratories 
(Maine, USA) and maintained in the Facility of Johns Hopkins Bloomberg School of 
Public Health. Mice were maintained in a low iron diet for five months. Food and 
distilled water was provided ad libitum. Because mice did not develop iron deficiency on 
the low iron diet, phlebotomy was performed with removal of 500 µl of blood three 
times. Three weeks after phlebotomy, mice were confirmed to be anemic by measuring 
Hb and ZnPPIX/heme ratio. Two days post anemia confirmation; groups were divided 
according to the different iron diets. A control non-anemic and an anemic group were 
included for each type of diet. Six groups were maintained on the new diets for 2 weeks 
and other 6 groups for 6 weeks. Anemia status was checked on day of liver harvest for 
the two-week diet experiment mice whereas the status on those with 6 weeks of diet were 
tracked 2 times before liver harvest and on day of sacrifice.  
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Female hepcidin Tg+ mice (C57BL/6 background) and female hemoglobin 
deficient or hbd mice (C57BL/6 background) were provided by Dr. Cindy Roy (JHMI).  
Hepcidin Tg+ mice carry both a tTA transgene (tetracycline transactivator protein) and a 
TRE.Hepc1 transgene (tetracycline response element fused with the hepcidin gene). The 
TRE.Hepc1 transgene is “off” in the presence of tetracycline. We maintained the gene 
“on” throughout the study without the addition of tetracycline. The hepcidin transgene is 
over expressed while endogenous hepcidin is still produced.  These mice mirror 
characteristics of anemia of chronic disease with a mild microcytic hypochromic anemia 
and mild elevation of reticulocytes counts. Their erythrocytes have a normal life span. 
Tg+ mice have decreased iron in hepatocytes with a shift of iron to the spleen and 
sequestration of iron in macrophages
151
.  
Hbd mice have an exon deletion in gene Sec15l1 (protein involved in the cycling 
of transferrin) making the uptake of transferrin iron defectuous in the erythroid precursor. 
Sec15l1 is homologous to a gene encoding a member of the exocyst pathway in yeast. 
These mice are hypochromic, with a decrease in hemoglobin and normal liver iron 
stores
152
.  Female C57BL/6 mice were used as control. Human exogenous hepcidin-25 
trifluoroacetate salt (Bachem, Bubendorf, Switzerland) at 1mg/ml was given 
intraperitoneally to a group Tg+ mice and C57BL/6 mice 4 hours before P. berghei 
inoculation.  
Male C57BL/6 mice were used for testing FBS0701 and were maintained in the 




3.3.3   Animal ethics 
All experiments were performed according to protocol “Iron and Murine Malaria” 
(Approval ID-MO09H403) approved by The Johns Hopkins Animal Care and Use 
Committee in accordance with institutional standards.   
 
3.3.4   Induction of anemia by phlebotomy  
Whole blood was collected by submandibular/facial bleeding. A Medipoint 
golden mouse lancet (Medipoint, Mineola, NY) sized 4 was used to stick mice in the 
temporal vein which traverses above the check pouch. The lancet allowed us to stick with 
enough pressure to insure a good blood draw making puncture as deep as the point of the 
lancet. Mice were bled in total 3 times with intervals of 3 days and then allowed to 
recover during 3 weeks. Every time ~500 µl of blood was collected with a subsequent 
replacement of the same volume with PBS (1X) by intraperitoneal route. Blood was 
stored at -80°C.  
 
3.3.5  Real-time in vivo imaging of luminescent Plasmodium on FBS0701 treated 
mice 
Thirty-six hours post infection with luciferase-expressing P. berghei parasites 
(parasite line 354cl4), shaved abdominal C57BL/6 mice were injected with 200 µl D-
luciferin dissolved in PBS (150mg/Kg; Caliper Life Sciences, USA) subcutaneously in 
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the neck. After five minutes, mice were injected intraperitoneally with 150 µl of Avertin 
to be anesthetized. Five minutes later, biolumiscence imaging was detected with a 12.5 
cm field of view (FOV), a medium binning factor and 180 seconds of exposure. For 
luciferase activity, mice whole bodies were visualized with the IVIS Imaging System 100 
(Xenogen- Caliper Life Sciences, USA). 
 
3.3.6 qReal-Time PCR quantification of liver infection and murine hepcidin level  
Balb/c, Hepcidin Tg+ and hbd mouse livers were collected and homogenized in 
TRizol (Invitrogen, Carlsbad, CA) and stored at -80C. Total RNA was isolated by adding 
chloroform and isopropanol and resuspending the RNA pellet in 75% ethanol. Pellets 
were finally dissolved in DEPC treated water and stored at -80C. Reverse transcription 
was performed with: random hexamers (50 µM), PCR buffer (1X), MgCl2 (5mM) dNTPs 
(4mM), RNAse inhibitor (1U/µl) and MuLV reverse transcriptase (2.5U/µl) from 
Applied Biosystems, Branchburg, NJ. The conditions for cDNA synthesis were: 25°C for 
10 min, 42°C for 20 min and 95°C for 5 min.  
Liver infection and murine hepcidin level were quantified by using P. berghei 
ANKA (PbA) 18s rRNA and Mouse hamp specific primers respectively. Multiplex qRT-
PCR reactions included 1X IQ Multiplex Power Mix (BioRad, Hercules, CA), 0.2 µM 
18s and hamp primers, 0.5 µM Hypoxanthine Guanine Phosphoriboayltransferase (hprt)  
primers (Gagliardi et al., 2011), 0.2 µM of each TaqMan probe and 3 µl (around 540 
ng/µl) cDNA for a total volume of 10 µl. Cycling conditions were followed according to 
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the BioRad CFX96: 95C for 3 min and 39 cycles of 95C for 10 sec and 55C for 30 sec. 
The gene copy number was normalized against the hprt housekeeping gene. The specific 
sequences of primers (Sigma Aldrich, Saint Louis, MO) were: 5’- 
GGAGATTGGTTTTGACGTTTATGCG-3’ and 5’- 
AAGCATTAAATAAAGCGAATACATCCTTA-3’ for 18s; 5’-
TGCAGAAGAGAAGGAAGAGAGACA-3’  and 5’- 
CACACTGGGAATTGTTACAGCATT-3’ for hamp and 5’- 
TCCCAGCGTCGTGATTAGC-3’ and 5’- 
CGGCATAATGATTAGGTATACAAAACA-3’ for hprt. The specific sequences for the 
probes (Integrated DNA Technologies, Coralville, IO) were: 5’ 6-FAM/ZEN-
CAATTGGTTTACCTTTTGCTCTTT-3’IBFC for 18s; 5’ TET-
CAACTTCCCCATCTGCATCTTCTGCTGT- 3’IBFQ for hamp and 5’ Cy5-
TGATGAACCAGGTTATGACC-3’BHQ-2 for hprt. Standardization curves were made 
with cDNA plasmids cloned with the TOPO TA cloning kit (Invitrogen, Carlsbad, CA).   
C57BL/6 mice livers were collected and homogenized with denaturing solution 
(4M guanidine thiocyanate, 25mM sodium citrate pH 7, 0.5% N-lauroylsarcosine and 
0.7% beta-mercaptoethanol and DEPC water) and stored at -80C. Total RNA was 
isolated by using the RNeasy Mini kit (Qiagen, MD). Reverse transcription was 
performed with the Transcriptor First Strand cDNA synthesis kit (Roche, Mannheim, 
Germany): random hexamers (60 µM), Transcription RT reaction buffer 1X, dNTPs 
(4mM), Protector RNAse inhibitor (20U) and Transcriptor Reverse Transcriptase (10U). 
The conditions for cDNA synthesis were: 25°C for 10 min, 55°C for 30 min and 85°C for 
5 min.   
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Liver infection was quantified by using PbA 18s rRNA specific primers. qRT-
PCR reactions included: 1X Power SYBR Green PCR Master Mix (Applied Biosystems, 
Warrington, UK) 0.2 µM 18s primers and 2 µl cDNA for a total volume of 20 µl. For 
normalization 18s primers were replaced by 0.2 µM Hypoxanthine Guanine 
Phosphoriboayltransferase (hprt) housekeeping gene primers in the reactions. Cycling 
conditions were as follow: 50°C for 2 min, 95°C for 10 min followed by 50 cycles of 
95°C for 15 sec and 60°C for 1 min. 
The specific sequences of primers were:  5’-CGG CTT AAT TTG ACT CAA 
CAC G-3’ and 5’-TTA GCA TGC CAG AGT CTC GTT C-3’ for PbA 18s rRNA and 5’ 
– TGC TCGAGA TGT GAT GAA GG – 3´ and 5’ – TCC CCT GTT GAC TGG TCA 
TT – 3’ for mouse hprt. 
 
3.3.7  Sporozoite infection 
Female mice were infected with 15,000 P. berghei ANKA sporozoites by tail vein 
injection. Thirty six hours post infection; mice were sacrificed with inhalation overdose 
of isoflurane. Livers were collected for qRT-PCR quantification of P. berghei infection 
load and mouse hepcidin expression and heart blood was collected for determination of 
anemic status. 
C57BL/6 male mice were infected with 10,000 luciferase - P. berghei sporozoites 
by eye injection post anesthesia with isoflurane. Thirty six hours post infection and post 
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bioluminescence assay infected mice were sacrificed with inhalation overdose of 
isoflurane. Livers were collected for qRT-PCR quantification of parasite infection load.  
 
3.3.8 FBS0701 testing 
Freshly made solutions of FBS0701 in water were administered by oral 
cannulation to C57BL/6 male mice. The effective dose of the drug was tested at 4 
different concentrations: 50, 100, 200 and 400 mg/kg. The interaction between FBS0701 
and primaquine was tested by reducing to half the effective dose of primaquine (from 
30mg/Kg to 15mg/Kg) and FBS0701 at 400 mg/kg. The interaction of the drugs was also 
evaluated at the level of survival. Blood was taken from the tail for smears and 
parasitemias were followed for 24 days. Parasitemias were determined in a blinded 
fashion by counting 4 fields of approximately 200 erythrocytes per field.  The effective 
schedule of drug administration was tested at 400 mg/Kg as follows:  -1; 0; +1; -1, 0, +1; 
-1, 0; 0, +1 days relative to infection on female Balb/c mice. 
 
3.3.9  Iron assays 
Blood was collected by retro-orbital bleeding from Avertin anesthetized mice into 
EDTA microtainer tubes (BD, Franklin Lakes, NJ). Mouse hemoglobin levels were 
determined based on the absorbance of samples at 540 nm using the Drabkin’s reagent 
(Sigma, St Louis, MO) following the instructions provided by the manufacturer. An 
aliquot of blood was placed on a cover glass (Aviv Biomedical Inc., Lakewood, NJ) to 
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quantify the ZnPPIX/heme ratio on the ZPP hematofluorometer (Aviv Biomedical Inc., 
Lakewood, NJ). Normal mouse ratios of ZnPPIX/heme in the literature range from 80 to 
120 µM ZnPPI / M heme 
153,154,155
. Livers and spleens from P. berghei infected female 
Balb/c mice were collected 2 days post infection and stored at -80C. Tissue nonheme iron 
was quantified as described by Cook with minor modifications
156
. Briefly, tissues were 
accurately weighted and digested on an acid solution containing HCl 3 M and 0.61M 
trichloroacetic acid for 50 h at 65ºC. Fifty microliters of the tissue extract were added to 1 
ml of working chromogen solution (5 vol of saturated sodium acetate, 5 vol of iron free 
water and 1 vol of chromogen stock containing 1.86 mM bathophenanthroline sulfonate 
and 143 mM thioglycolic acid). Samples were incubated for 10 minutes at room 
temperature. Absorbance was determined at 535 nm. An iron standard curve diluted on 
acid solution was made with ranging concentrations from 200 µg/dl to 1000 µg/dl. 
Measurements were expressed as micrograms of iron per gram of tissue.  
 
3.3.10 Statistical analysis 
To observe the effect of hepcidin on parasite level we displayed the means of 
parasite across four groups of mice: (a) normal mice, (b) normal mice that received 
hepcidin, (c) overexpressing-hepcidin-transgenic mice, and (d) overexpressing hepcidin 
transgenic mice that received hepcidin.  
We performed simple linear regressions to model the relationship between diet 
and parasite level, and between diet and hepcidin level at 2 weeks and at 6 weeks after 
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receiving the iron diet. In all cases we stratified the regressions by anemic status to 
compare the slopes and to detect the effect modification caused by anemia. To regress 
hepcidin on iron in diet, we used a spline with a knot at iron = 200 µg, which corresponds 
to the normal diet group. We transformed values of parasite level, hepcidin level, and 
iron in diet to log10 scale to control for the right skewness of the data. All analyses and 
graphs were produced in R* and all statistics were evaluated at an alpha level of 
0.05
157
.To analyze the experiments of FBS0701 effect on liver infection and transgenic 
mice we used a t-Student test and a Wilcoxon test. Statistics were evaluated at an alpha 
level of 0.05. 
 
3.4  Results 
3.4.1 FBS0701 reduces Plasmodium liver parasite numbers  
To study of the importance of iron for the hepatic stage of the parasite we tested 
the effect of the iron chelator FBS0701 which has a hepatic clearance. We found a dose-
response on decreasing parasite load as shown by the bioimaging assay (Figure 3.1) and a 
statistically significant reduction between the non treated (0 mg/kg) and the FBS0701 
treated mice at 400 mg/kg (t-Student test=3.25; p-value=0.043).  
To test the effect of complete clearance of parasites, mice received FBS0701 at 
1000 mg/kg and showed a statistically significant reduction of liver infection. Parasite 
load was evaluated by bioimaging (Figures 3.2A-B, t-Student test = -4.6619; degrees of 
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freedom = 5.77; p-value = 0.004) and by qReal-time PCR to make it more accurately 
(Figure 3.2C, t-Student test = -3.42; degrees of freedom = 4.18; p-value = 0.025).   
Results showed that mice treated with FBS0701 and primaquine combined induce 
a significant reduction (Wilcoxon test statistic = 16; p-value = 0.02857) of the parasite 
load compared to control.  Primaquine or FBS0701 alone induced a reduction of parasite 
load. However, the difference between primaquine or FBS0701 and the untreated control 
was not statistically significant, likely because of the small sample size (Figure 3.3).  The 
positive effect of the combination therapy was also reflected on a more prolonged 
survival. Mice from the non treated (control), FBS0701 and primaquine groups alone 
showed symptoms of cerebral malaria. Mice began dying on these groups from day 6 
post infection whereas those mice receiving combined drugs survived for 23 days post-
infection, although they were sacrificed for being very weak and anemic at that time 
(Figure 3.4).   
Also, FBS0701 was found to be more effective given at one day post liver stage 
infection, similar to the treatment of murine blood stage infection
158
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Figure 3.1. FBS0701 showed a dose-response behavior on infected mice. Male C57BL/6 mice in groups 
of 4 were treated with FBS0701 at concentrations of 50, 100, 200 and 400 mg/kg. Control mice (0mg/kg) 
did not receive any drug at all. Initially mice were infected with 10000 Luciferase – expressing P. berghei 
sporozoites by eye injection. Drug was given orally 4 hours before infection. Forty hours after infection, 
control and treated mice were injected with luciferin upon anesthesia and their hepatic infection load was 
quantified by luminescence and expressed by Relative Luminescence Units (RLU). All treatment groups 
were compared to the control group with t-Student test. The group that received 400 mg/kg FBS0701 
reported the lowest level of infection and was the only group that was statistically different than the control 
group (t-Student test=3.25; p-value=0.043). Asterisks show the groups that were statistically significant A. 
Real time in vivo imaging of infected mice by luminescence. Each panel represents all the control (Ctrl, no 
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Figure 3.2. FBS0701 at 1000mg/kg induced a significant decrease of hepatic parasite close to 
clearance. Male C57BL/6 mice in groups of 5 were treated with FBS0701 at 1000 mg/kg (mice F1 –F5) or 
were left untreated (control mice, C1-C5). Initially mice were infected with 10000 Luciferase – expressing 
P. berghei sporozoites by eye injection. Drug was given orally 4 hours before infection. Forty hours after 
infection, control and treated mice were injected with luciferin upon anesthesia and their hepatic infection 
load was quantified by luminescence and expressed by Relative Luminescence Units (RLU) and were later 
sacrificed to collect their livers for parasite quantification by qReal-Time PCR. A-B. Real time in vivo 
imaging by luminescence of infected mice (t-Student test = -4.6619; degrees of freedom = 5.77; p-value = 
0.004). Each panel on A represents all the control (C, no drug) and treated mice with 1000 mg/kg of 
FBS0701 (F). C. qReal –Time PCR quantification of infected mice (t-Student test = -3.42; degrees of 
freedom = 4.18; p-value = 0.025).   
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Figure 3.3. FBS0701 and primaquine combined induce a significant hepatic parasite decrease in 
comparison to their effects when administered alone. Male C57BL/6 mice in groups of 4 were treated 
with FBS0701 (F) at 400mg/kg and/or primaquine (PQ) at 15mg/kg. Control mice (ctrl) did not receive any 
drug at all. Mice were infected with 10000 Luciferase – expressing P. berghei sporozoites by eye injection. 
Drugs were given orally 4 hours before infection. Forty hours after infection, control and treated mice were 
injected with luciferin upon anesthesia and their hepatic infection load was quantified by luminescence and 
expressed by Relative Luminescence Units (RLU). The effects of FBS0701 and primaquine alone did not 
differ statistically between them. During the experiment, 2 mice died in the group that received primaquine 
alone. Each treated groups was compared against the control group (no drug). Asterisks indicate the groups 
that were statistically significant.  A. Real time in vivo imaging of infected mice by luminescence. Each 
panel represents all the control (Ctrl, no drug) and treated mice according with primaquine (P) or FBS0701 
(F) or combined (P + F) B. Analyzed data from A. (Wilcoxon test statistic  = 16; p-value = 0.02857).  
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Figure 3.4. Mice that were treated with FBS0701 and Primaquine combined showed a higher 
survival. Male C57BL/6 mice, from the previous experiment, infected with 10000 Luciferase – expressing 
P. berghei sporozoites were tracked until the last mouse died or had to be sacrificed for its weakness. Mice 
that received FBS0701 (FBS) and primaquine (PQ) combined survived until day 24, when they had to be 
sacrificed for being severely sick and anemic from malaria. Mice that received drugs alone or no drug 
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Figure 3.5. FBS0701 showed to be more effective at controlling hepatic parasite load when given one 
day post infection. Schedule of supplementation of FBS0701 (FBS). Days relative to infection: I, -1 day; 
II, 0 day; III, +1; IV, -1,0,+1 days; V, -1,0 day; VI, 0,+1. FBS0701 was given at 400 mg/kg orally. Control 
mice did not receive drug at all. Mice in groups of 5 were infected with 15000 P. berghei sporozoites by 
tail vein injection. Forty hours after infection, control and treated mice were sacrificed to collect their livers 
for parasite quantification by qReal-Time PCR. Parasite load average and standard deviations are 


































Plasmodium  infection levels at different FBS00701 schedules 
77 
 
3.4.2 Transgenic hepcidin mouse (Tg+) and hemoglobin deficient mouse (hbd) 
malaria indicate that hepcidin controls bioavailable iron important for hepatic 
parasite development 
We next studied a group of transgenic hepcidin mice (Tg+), which has lower liver 
iron stores, and a hemoglobin deficient murine group that has normal liver stores but is 
anemic from an erythrocyte defect in the iron/transferrin uptake. The study showed that 
in comparison to C57BL6 control mice, overexpressing hepcidin transgenic mice (Tg+ 
mice) resulted in a lower parasite load with a similar effect from receiving extra 
exogenous hepcidin (Figure 3.6); however, we did not find a statistically significant 
difference in this analysis (Kruskal-Wallis chi-squared = 4.6287, degrees of freedom = 3, 
p-value = 0.20). Hemoglobin deficient mice showed a non-significant difference (t-
Student test=1.46; p-value = 0.21) between their loads of Plasmodium infection 
compared to C57BL6 control mice. Normalized hepcidin levels in hbd mice were 




















Figure 3.6. Transgenic hepcidin mice after receiving exogenous hepcidin showed a lower parasite 
load while parasite loads on hemoglobin deficient mice were not different compared to control mice. 
A. Two groups (4 each) of anemic transgenic hepcidin mice (Tg+), and two groups (4 each) of non-anemic 
wild type mice (C57BL6 or B6) were infected with 15,000 P. berghei sporozoites by tail vein injection. On 
day of infection one wild type group (C57BL6 + hep) and one transgenic group (Tg+ + hep) received 
exogenous hepcidin (1 mg/ml) by intraperitoneally.  Two days after infection mice were sacrificed and 
theirs livers were collected to quantify hepatic infection level by qReal time PCR. We found a negative 
trend of parasite load with overexpression of endogenous and exogenous hepcidin and the combination of 
both (Kruskal-Wallis chi-squared = 4.6287, degrees of freedom = 3, p-value = 0.20). B.  A group of 4 non-
anemic mice wild type mice (C57BL6) and 4 hemoglobin deficient (hbd) mice were infected and analyzed 
as described on A, however none of the mice received exogenous hepcidin. Hbd mice showed a non-
significant difference between their parasite loads compared to control mice (t-Student test=1.46; p-value = 
0.21). Normalized hepcidin levels in the liver of hbd mice were 1.97E+04 in the setting of severe anemia. 
Additional information: Hb is 9.9 g/dl and HCT % is 38 on hbd mice; Hb is 12.6 g/dl and HCT% is 42 on 
C57BL6 mice. NS = not significant        
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3.4.3 Phlebotomy induces iron deficiency anemia in mice 
We obtained just weaned Balb/c mice and maintained them on a low iron diet for 
approximately 4 months. The mice never developed anemia. We next performed three 
bleeds of approximately 500 to 600 µl (each time) over a week time period replacing the 
volume with 1X PBS. Values of hemoglobin and ZnPPIX/heme ratios showed, that after 
bleeding mice 3 times removing about 1.5 ml to 2 ml in total, we induced anemia and 
iron deficiency. The cut off chosen for anemia was 12 g/dl (mice with Hb lower than 12 
g/dl were considered anemic) and for iron deficiency was 160 µM/M (mice with a ratio 
higher than 160 ZnPPIX µM/hemeM were considered iron deficient). In cases where the 
hemoglobin level was very close to our cut off we used the hematocrit percent to decide 
determine the anemic status (HCT lower than 45%); although the HCT parameter was 
only included in the second repetition of the experiment. Consistently, on both repetitions 
anemic iron deficient mice maintained their anemic status and iron deficiency after two 
and six weeks under a low iron diet. On the first biological repletion we observed that 
non-anemic mice were not rendered anemic or iron deficient by a low iron diet. In the 
second biological repetition, non-anemic mice with a low iron diet for 2 weeks reported a 
borderline value for iron deficiency whereas non-anemic mice with a low iron diet for 6 
weeks showed a value higher than 160 µM/M. However, in both cases their non-anemic 







 Baseline level On day of liver harvest 
 



















Low 11.7 4.0 Yes 249.4 70.2 Yes 9.1 3.2 Yes 173.5 15.3 Yes 
Normal 10.6 2.6 Yes 229.4 29.8 Yes 13.3 1.4 No 154.2 10.7 No 
High 11.3 0.3 Yes 239.3 30.5 Yes 12.8 1.1 No 136.8 6.1 No 
6 
Low 9.5 1.3 Yes 245.2 36.1 Yes 7.3 2.3 Yes 247.8 111.2 Yes 
Normal 8.4 2.2 Yes 368.0 116.8 Yes 12.8 0.5 No 131.3 3.4 No 




Low ND  ND ND  ND 13.3 0.4 No 144.2 4.6 No 
Normal ND  ND ND  ND 12.9 0.4 No 148.2 6.2 No 
High ND  ND ND  ND 12.2 1.2 No 141.2 6.4 No 
6 
Low ND  ND ND  ND 14.5 2.6 No 139.4 12.0 No 
Normal ND  ND ND  ND 15.1 1.2 No 140.6 3.6 No 
High ND  ND ND  ND 15.2 0.9 No 109.4 9.3 No 
Control mice (not bled with 
normal diet) 
17 1.8 No 167 10.7 No 






































Low 17.2 3.1 11.6 0.9 Yes 255.8 18.1 Yes 19.0 4.5 4.8 1.2 Yes 382.8 87.7 Yes 
High 22.5 6.0 12.5 3.0 Yes 260.3 17.2 Yes 49.2 2.9 12.5 0.6 No 143.3 5.7 No 
6 
Low 19.5 7.8 11.1 3.6 Yes 339.0 55.7 Yes 22.3 12.2 5.2 3.0 Yes 507.0 141.8 Yes 





Low ND  ND  ND ND  ND 49.9 0.9 13.0 0.2 No 161.8 7.4 Yes 
High ND  ND  ND ND  ND 50.7 0.5 13.4 0.3 No 156.0 10.0 No 
6 
Low ND  ND  ND ND  ND 47.2 3.7 12.1 0.5 No 199.3 12.8 Yes 
High ND  ND  ND ND  ND 46.4 4.9 11.3 1.3 No 158.8 14.5 No 
Control mice (not bled 
with normal diet) 
47.4 2.4 15.6 1.0 No 152.7 11.2 No 
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Table 3.1. Mice were rendered anemic and iron deficient after phlebotomies. Mice were 
phlebotomized 3 times removing around 1.5 to 2 mL in total. Blood samples were analyzed for hematocrit 
(HCT) %, Hemoglobin (Hb) and ZnPPIX/heme. Baseline level refers to the values obtained right before the 
change in iron diets. Day of liver harvest refers to the values obtained on the sacrifice day of mice post 
infection with P. berghei sporozoites. A. Corresponds to the first biological experiment considering a low, 
normal and high iron diet. B. Corresponds to the second biological repetition considering only a low and 
high iron diet. Balb/c control mice were never phlebotomized and received a normal iron diet. The cut off 


















3.4.4 Only hepatic Plasmodium parasite loads from anemic mice maintain a strong 
negative relationship with increasing iron in diet  
Initially we tested low, normal and high iron diets. On our first experiment  (1
st
 
biologic repetition) we found that after 2 weeks of feeding on iron diets, parasite load 
showed a negative relationship with increasing levels of iron in the diet in anemic and 
non-anemic mice and this negative relationship was not statistically different between 
anemic and non-anemic mice (p=0.93) (Figure 3.7A). After 6 weeks of either iron diet, 
parasite load maintained a negative relationship with increasing levels of iron diet only in 
anemic, iron replete mice. Non-anemic mice showed a weaker negative relationship 
between parasite load and iron diet. This difference in the relationship of parasite load 
and iron diet between anemic and non-anemic mice was statistically significant (p < 
0.001) (Figure 3.7C). We repeated the experiment (2
nd
 biologic repetition), this time we 
only examined a low and high iron diet for 2 weeks and 6 weeks. We observed a negative 
relationship in the anemic iron deficient group, with increasing concentrations of iron 
diets. Non-anemic showed a weaker negative relationship.  The difference in the effects 
on anemic and non-anemic mice was statistically significant (p=0.01) (Figure 3.7A). At 6 
weeks, anemic and non-anemic groups showed a negative relationship with increasing 
concentrations of iron diets. The difference in the relationship between the parasite load 
and iron diet between anemic and non-anemic mice was not statistically significant 
(p=0.20) (Figure 3.7C). We decided to make a pooled data analysis from both repetitions. 
We found that after 2 weeks of iron diets, the anemic and non-anemic groups had a 
negative relationship with increasing concentrations of iron, although the non-anemic 
group showed a slightly weaker negative relationship. The difference between the two 
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groups was not significant (p=0.24) (Figure 3.7B). We observed a similar effect at 6 
weeks on the pooled data, however this time the difference in the relationships between 
parasite load and iron diets between anemic and non-anemic was statistically significant 
(p=0.01) (Figure 3.7D).  
As depicted on the bar graphs (Figure 3.8) obtained from the pooled data, we 
observed that the number of parasites after 2 weeks was higher in the anemic mice 
compared to the non-anemic mice under a low iron diet but higher in the non-anemic 
compared to the anemic under a high iron diet. However, differences were not 
statistically significant. Also, it was shown that non anemic mice had higher numbers of 
parasites with a low iron diet compared to a high iron diet, but this difference was not 
significant. Anemic mice under a low iron diet reported a higher parasite load that was 
statistically significant compared to anemic mice receiving a high iron diet (p<0.001). 
After six weeks, we observed again higher parasites numbers in the anemic compared to 
non-anemic under a low iron diet, but this difference was not significant. We found a 
statistically significant higher parasite load in non-anemic compared to anemic mice with 
a high iron diet (p=0.007). Comparison between non anemic mice with a low iron diet 
and a high iron diet showed that with a low iron diet the number of parasite was 
statistically significantly higher (p=0.03). Similarly, anemic mice with a low iron resulted 
in higher number parasites compared to anemic mice under a high iron diet. This 
difference was significant (p<0.01).  Also, we evaluated if there was a statistical 
interaction between iron supplementation and anemic status at 2 and 6 weeks. We found 
that the increase in parasite load in non-anemic mice after an increase in iron 
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concentration was significantly higher than in the case of anemic mice. This interaction 





























Figure 3.7. After 2 weeks of iron diets, hepatic parasite loads showed a negative relationship with 
increasing concentrations of iron diets in anemic and non-anemic mice whereas after 6 weeks, 
parasite load maintained a stronger negative relationship only in anemic mice. After bleeding, anemic 
iron deficient mice and non-anemic iron replete mice, in groups of five, were given iron diets with 
increasing concentrations of the metal. Diets were given for 2 weeks and 6 weeks ad libitum. Upon 
completion 2 or 6 week interval, anemic and non-anemic mice were infected with 15000 P. berghei 
sporozoites by tail vein injection. Forty hours after infection mice were sacrificed and their livers were 
collected to quantify hepatic infection level by qReal- Time PCR. A. Parasite level vs. Iron diets after 2 
weeks showing the two repetitions.  B. Pooled data from A. C. Parasite level vs. Iron diets after 6 weeks 
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Figure 3.8. Bar graphs confirming the effect analyzed by linear regressions of the pooled data 
depicted on figure 3.7. Only high and low iron diets were considered for a better comparison. The trend of 
higher parasite load in the non-anemic mice under a high iron diet became much more evident at six weeks. 
A. Parasite load vs. iron diet after 2 weeks (based on the pooled data). B. Parasite load vs. iron diet after 6 
weeks (based on the pooled data). P-values were obtained from a T- Student test. One analysis was made 
comparing the effects on parasite numbers between anemic and non-anemic mice under a low and high iron 
diet after 2 and 6 weeks and a second analysis was made comparing the effects on parasite numbers 
between low and high iron diet groups under anemic and non-anemic status after 2 and 6 weeks. Only 






P < 0.001 
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P = 0.007 
P < 0.01 




3.4.5   Increasing iron in diet increases hepcidin levels in livers of anemic and non-
anemic mice 
Contrary to the trend that we found between iron diets and parasite loads, our 
experiments showed a positive relationship between increasing levels of iron diet and 
hepcidin in anemic and non-anemic groups. Increasing iron increases hepcidin. On the 
first repetition, this positive relationship was very distinctive when iron increases from 
low to normal levels and it levels off after that. This positive relationship was different 
between anemic and non-anemic mice when the iron diet was below normal levels 
(p=0.001 at 2 weeks and p=0.008 at 6 weeks) (Figures 3.9A and 3.9C). However, the 
significant difference was lost above normal levels of iron diet (p=0.103 at 2 weeks and 
p=0.474 at 6 weeks) (Figures 3.9A and 3.9C). This relationship was observed after 2 and 
6 weeks of receiving the iron diet. On the second repetition, the positive relationship 
between hepcidin and iron diets was shown again. The positive relationship of hepcidin 
and iron diet when comparing anemic and non-anemic mice, was significantly different 
(p<0.001 at 2 and 6 weeks) (Figures 3.9A and 3.9C). Similarly to the parasite load, we 
performed a pooled data analysis from both repetitions. The inclusion of the normal iron 
diet on the analysis made that the positive relationship between anemic and non-anemic 
mice was significantly different when iron diet was below normal levels (p=0.03 at 2 
weeks and p=0.016 at 6 weeks) (Figures 3.9B and 3.9D). The significant difference was 
lost above normal levels of iron diet (p=0.61 at 2 weeks and p=0.45 at 6 weeks) (Figures 
3.9B and 3.9D). This data confirms that once iron stores are replete, hepcidin is not 
sensitive to further increases because it is expressed at nearly the maximum level.  
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As shown on the bar graphs (Figure 3.10) from the pooled data;  non-anemic mice 
showed higher hepcidin level compared to anemic under a low iron diet, this difference 
was statistically significant (p=0.006 at 2 weeks; p =0.001 at weeks). Anemic mice 
showed higher hepcidin levels compared to non-anemic under a high iron diet; however 
this difference was not significant. A comparison between no anemic mice under a low 
iron diet and a high iron diet revealed that hepcidin levels are significantly higher after a 
high iron diet (p<0.001 at 2 weeks; p=0.03 at 6 weeks). Similarly, hepcidin levels were 
statistically significant higher in anemic mice under a high iron diet compared to a low 




























Figure 3.9.  After 2 and 6 weeks of iron diets, high iron diet equals high levels of hepcidin in anemic 
and non-anemic mice. Anemic mice under low iron diet showed low hepcidin level. After rendering 
anemic mice, anemic and non-anemic mice, in groups of five, were given iron diets with increasing 
concentrations of the metal. Diets were given for 2 weeks and 6 weeks ad libitum. Upon completion with 
the diet time, anemic and non-anemic mice were infected with 15,000 P. berghei sporozoites by tail vein 
injection. Forty hours after infection mice were sacrificed and their livers were collected to quantify 
hepcidin level by qReal time PCR. A. Hepcidin level vs. Iron diets after 2 weeks showing the two 
repetitions.  B. Pooled data from A. C. Hepcidin level vs. Iron diets after 6 weeks showing the two 
repetitions.  D. Pooled data from C 
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Figure 3.10. Bar graphs confirming the effect analyzed by linear regressions of the pooled data 
depicted on figure 3.9. Only high and low iron diets were considered for better comparison. The behavior 
of higher levels of hepcidin in anemic and non-anemic mice under a high iron diet was the same after 2 and 
6 weeks. A. Hepcidin level vs. iron diet after 2 weeks (based on the pooled data). B. Hepcidin level vs. iron 
diet after 6 weeks (based on the pooled data). P-values were obtained from a T- Student test. One analysis 
was made comparing the effects on parasite numbers between anemic and non-anemic mice under a low 
and high iron diet after 2 and 6 weeks and a second analysis was made comparing the effects on parasite 
numbers between low and high iron diet groups under anemic and non-anemic status after 2 and 6 weeks. 








Hepcidin, anemia and iron diet at 2 weeks 
P =0.001 




3.4.6   Nonheme iron quantification in liver and spleen correlates to iron 
concentration of diets  
On the second repetition, after phlebotomy, iron diets and Plasmodium infections; 
we took portions of the spleens and livers to quantify tissue iron. We found that levels of 
nonheme iron were higher in the livers and spleens of mice that received a high iron diet 
regardless of their anemic status and time with the diets and that there is a drop of iron 
between 2 and 6 weeks. Anemic mice with a low iron diet showed the lowest levels of 














Table 3.4. Nonheme iron on spleens and livers from anemic and non-anemic mice under low and high 
iron diet. Portions of spleens and livers were taken on day of liver harvest, 36 hours post infection with 
15,000 P. berghei sporozoites. Tissues were digested in acid solution for 50 h at 65ºC and iron was 
quantified with a chromogen reagent containing bathophenanthroline sulfonate at 535 nm.  Tissues 
quantified correspond to the animals from the second repetition only. Measurements were expressed as 








    Liver Spleen 
 
Weeks Iron diet 
Total non heme 
iron  mean (ug/g) 
stdev 
Total non heme 





Low 18.6 2.4 30.3 11.1 
High 1040.3 167.2 393.9 83.2 
6 
Low 38.9 12.1 16.7 5.0 





Low 50.2 15.3 130.5 12.7 
High 798.3 107.9 485.4 61.7 
6 
Low 51.0 18.1 127.2 71.2 




Different studies have shown the importance of iron for blood and hepatic stages 
of Plasmodium.  One recent reference highlighted the importance of iron on erythrocytes 
for the parasite (personal communication by Carla Cerami Hand). Similarly, we studied 
the importance of iron in hepatocytes for hepatic stage development.  
The use of transgenic mice overexpressing hepcidin (Tg+) and hemoglobin 
deficient mice (hbd) were chosen over other transgenic anemic mice on the basis of 
different iron deficient compartments, either in the liver or the erythroid compartment. 
Tg+ mice have normal to low erythroid iron, higher iron in macrophages and low iron in 
hepatocytes whereas hbd mice have very low erythrocyte iron, but unchanged hepatocyte 
iron stores. Based on these conditions we thought that if iron location was important for 
the parasite, Tg+ mice would have a decrease in liver stage malaria and on the contrary 
hbd mice would have unaffected liver stage infection compared to control mice. Our 
results supported these hypotheses and showed that iron compartmentalization is indeed 
important during liver stage infection.   
Facial bleed was a good method to induce anemia in mice compared to diet 
induced anemia (tried at the beginning without success, data not shown). Besides anemia, 
phlebotomy can also induce hypoxia, increased Epo and erythropoiesis and decreased 
hepcidin mRNA
159
. We were able to maintain anemia and iron deficiency for both 2 and 
6 weeks of the low iron diet.   
Mice receiving a standard diet in the laboratory need at least 2 weeks of an iron 
deficient diet to decrease the basal hepcidin expression, when diet is changed to a higher 
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iron diet, the increased response begins at 24 h and is maintained during all the time mice 
are fed with the same diet
149
. This effect was seen in our anemic mice after 2 weeks and 6 
weeks of high iron diets. Once hepcidin is produced, it causes an eventual redistribution 
of iron from hepatocytes to macrophages. With less bioavailable iron within hepatocytes 
it is expected that the development of parasite may be compromised. In our study we did 
find a direct increasing correlation between higher hepcidin and high iron diets with both 
the 2 and 6 week intervals.  
The iron chelator FBS0701 showed a dose – response effect on the infection level 
and was able to reduce significantly the parasite load with a high concentration (1000 
mg/kg). Primaquine, a known antimalarial to treat hypnozoites (stage on hepatocytes) 
showed a synergistic effect with FBS0701. This suggests that the new iron chelator could 
be used in a combination therapy to treat not only blood stages but also liver stages. We 
found not statistical significance between the different dose schedules, although we found 
a trend of reduction in parasite load when drug was given on a single dose post infection 
(capable of curing mice with a blood stage infection
158
) and when it was given -1, 
0,+1days. The spike on day 0 disappears once outlayer values are removed. The liver P. 
berghei growth takes approximately 48 hours in a mouse. Considering that parasites 
begin to replicate at 24 hours and the plasma concentration of FBS0701 at 1 hour is 17.5 
µM and at 24 h is around 0.1 µM it would explain why FBS0701 can be apparently more 
effective at the mentioned schedules: iron chelation to deprive from iron enzymes 
involved in replication. Under this idea we should see a similar effect in the last schedule 
(0,+1), however this was not the case. We suggest a repetition of the experiment to see if 
data are consistent.           
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In our experiments we used about ten times the sporozoite inoculum given by 
mosquitoes for the qReal-Time PCR or bioluminescent imaging. We have not proven but 
predict that the effect of FBS0701 possibly may prevent blood stage infection with 
mosquito inoculum of sporozoites which deliver a few hundred sporozoites rather than 
the experimental doses of 10,000 used here. A single human dose of FBS0701 is 
predicted to remove about 20-30 mg of iron over a 24 hour period. This amount should 
not affect total iron status in a short 3-5 day treatment regimen for malaria. Critically 
FBS0701 perturbs bioavailable iron for the liver and erythrocyte Plasmodium parasite. 
 A collaborator, Carla Cerami Hand had focused on human P. falciparum 
response to iron supplementation in anemic and non-anemic individuals. We focused on 
liver stage malaria quantification in liver stage malaria mouse model. The mice received 
iron-supplemented diets and at baseline were both anemic and iron deficient as measured 
by elevated ZnPPIX to heme ratios or at baseline were neither anemic nor iron deficient. 
Our results from the two biologic replicate experiments showed that parasite liver levels 
in anemic mice had a strong negative correlation with high iron diets after 2 and 6 weeks. 
The low parasite liver levels were inversely correlated with a recent increase in hepcidin 
values. However, at 2 weeks we observed only weak negative relationship with the iron 
diets in the non-anemic group (this may be explained by the increased variability in non-
anemic mice on high diet). Also, we confirmed that the difference in parasite numbers 
between the anemic and non-anemic groups receiving a high iron diet was not significant.  
Probably, during this time, this effect was caused by the increased expression of hepcidin 
as a response to increasing concentrations of iron in the serum and regardless of the iron 
stores on iron-replete mice (non-anemic). After 6 weeks of iron diets, results on non-
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anemic mice showed that the effect of endogenous iron stores along with iron 
supplementation was more predominant than the action caused by endogenous hepcidin 
(induced by iron loading). We observed higher level of liver parasites with increasing 
iron diets. Therefore, we were able to partially replicate the findings in Pemba, that there 
was an increased incidence and severity to disease in iron replete children, after 6 weeks 
of diet, but began to see this trend at 2 weeks. Also, the study published by Portugal et al, 
showed that when non-anemic mice received 3 doses of ferric ammonium citrate 24 h and 
4 h before and 20 h post infection with sporozoites, they had a significant higher parasite 
load in the liver compared to control mice
9
. Here, the time of iron supplementation was 
much shorter than in our studies, but probably because mice were already iron replete and 
they received 3 continuous doses of ferric ammonium citrate at 250mg/kg they had the 
same effect we observed clearly after 6 weeks of diet.      
Portugal et al. demonstrated the importance of iron compartmentalization for 
parasite development mediated by hepcidin
9
. We have also demonstrated the importance 
of iron in transgenic mouse models of disordered iron homeostasis (Tg+ and hbd mice) 
and on our phlebotomized anemic mice after 2 weeks of iron supplementation, and the 
correlation between hepdicin and diets and parasite loads. In general, we postulate that in 
the hepcidin-iron-infection axis, hepcidin plays a main role acutely whereas the presence 
of iron itself (through supplementation in this case) is predominant over time. A recent 
increase in hepcidin will limit bioavailable iron in the liver and decrease parasite liver 
load. The same hepcidin level after 6 weeks does not maintain low bioavailable iron in 
the face of iron supplementation. With iron supplementation after a few weeks we see an 
increase in parasite liver levels. However, this may not be the only factor influencing our 
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results. The quantification of nonheme iron on the spleen and liver tissues showed that 
liver iron is actually dropping between 2 and 6 weeks. This may be a “first pass” effect. 
Blood flows from the serosal side of the duodenum to the liver first. There, the iron is 
recovered and stored by the liver, but eventually gets loaded into new red cells. When 
they are phagocytized by macrophages of the spleen, then spleen iron eventually 
increases.  The fact that anemic mice have the lowest spleen iron levels correlates with 
the use of splenic iron for stress erythropoiesis in these mice. Also, the spleen iron levels 
correlate well with the increasing levels of hepcidin found when giving a high iron diet 
(therefore increasing the levels iron in the serum). The question is why if the iron levels 
on the livers of anemic mice are higher or very close to those of non-anemic mice, and 
considering that hepcidin is also being increased simultaneously, parasites loads on those 
anemic mice are not high. We believe that in the context of non anemia (or iron replete 
individuals) along with iron supplementation, exogenous iron induces the increase in 
hepcidin, which would target ferroportin present on Kuffer cells and hepatocytes 
inducing the degradation of the iron exporter, causing the accumulation of iron within 
those cells. But in the context of anemia and iron supplementation, the responsiveness of 
ferroportin in the hepatocytes would be reduced allowing the export of iron from those 
cells. The heme iron quantification assay did not allow us to discriminate iron from 
macrophages or hepatocytes.    
There are several studies that have evaluated the importance of iron by itself and 
the efforts of parasites to obtain the metal. Alburquerque et al. have shown that parasites 
can remodel infected cells to facilitate their development. Hepatoma cells infected with 
Plasmodium showed a decrease of ferroportin and an increase of DMT-1 to favor 
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accumulation of iron in hepatocytes
160
. Clark et al. showed that, without considering the 
effect of hepcidin on iron regulation, deficient anemic patients who received iron 
supplementation increased their erythropoiesis and replaced their microcytic iron-
deficient RBCs with new normocytic and iron-replete RBCs. The change in RBC 
physiology and population would favor blood stage infection. Lastly, this same group 
proved that parasitized RBCs increase their labile iron pool along with the parasite life 
cycle and needs. They confirmed that parasites can even access iron sources from host 
serum
161
.      
Therefore, our hypothesis is that hepcidin reaches a plateau causing a 
redistribution of iron and subsequently influences the decrease of parasites and, once 
reached that level, hepcidin effects become less significant in the presence of a 
continuous inducer of parasite growth like iron supplementation.  
In conclusion, based on the importance of iron for the parasite and the human 
host, it would seem more reasonable to put in practice the recommendation of iron 
















EFFECT OF ANTIMALARIAL IRON CHELATOR FBS0701 ON PLASMODIUM 










4.1 ABSTRACT  
 Current efforts to fight against malaria include both antimalarial drugs and 
vaccines. Iron chelators have been studied as promising drugs due to its antimalarial 
properties against different stages of the parasite in vitro and in vivo. The new iron 
chelator FBS0701, already tested in Plasmodium blood stages, was shown to affect 
development of early, not late P. falciparum gametocytes and to cure P. yoelii infected 
mice. Here we tested the effect of FBS0701 on late stage P. falciparum gametocyte 
infectivity to mosquitoes. Incubation of mature gametocytes for 24, 48 and 72 hours with 
increasing concentrations of FBS0701 (12.5-50 µM) resulted in a significant reduction in 
mosquito infectivity measured by the oocyst number per mosquito and up to 96% 
reduction in prevalence (% infected mosquitoes). This reduction in mosquito infectivity 
was due to mortality of gametocytes as shown by propidium iodide staining and 
exflagellation assays despite minimum morphologic changes by Giemsa blood film. Pre 
incubation of FBS0701 with ferric chloride restored the gametocyte infectivity showing 
that the inhibitory effect of FBS0701 was a result of iron chelation. 
 Deferoxamine, another iron chelator also reduced gametocyte infectivity but to a 
lesser extent.  Finally, co-feeding the gametocytes together with FBS0701 to mosquitoes 
did not significantly change the oocyst numbers, suggesting that iron chelation by 
FBS0701 is not detrimental for the sexual stages of the parasite inside the mosquito 
midgut. These results show the importance of gametocyte iron metabolism as a potential 




4.2  INTRODUCTION 
Malaria remains a major health problem in tropical and subtropical regions. As 
estimated by WHO in 2012 there were 207 million infected people and around 627 000 
deaths in the world
162
. One of the main problems to control malaria transmission is the 
detection and treatment of gametocyte carriers. These include people treated for the 
asexual stages of malaria that might have circulating gametocytes for up to a month after 
the treatment and asymptomatic malaria patients that without treatment could have 
circulating gametocytes for many months
163
. Current efforts to control malaria 
transmission include the improvement of methods to detect gametocyte carriers as well as 
the development of transmission-blocking drugs and vaccines which aim to interrupt 
parasite reproduction and development in the vector. 
The quinolines like chloroquine and quinine have minimal effects on mature 




Studies show that quinine and mepacrine increase the number of gametocytes and 
therefore transmission to mosquitoes
167
. Chloroquine and quinine affect early 
gametocytes by disrupting hemoglobin degradation whereas  atovaquone inhibits 
cytochrome b, important for the mitochondrial membrane potential
164
. None of these 
drugs affect late gametocyte stages
167,168
. Artemisinin-based combination therapy (ACT) 
reduces gametocytes circulating in the blood by targeting early gametocytes, although 
transmission can still occur after treatment
169,170
. Primaquine, the only drug currently 
used to target mature P. falciparum gametocytes
171
 and other 8-aminoquinolines can kill 
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mature P. falciparum gametocytes
172
, however, they have poor activity against asexual 
stages and might target mitochondrial function
173
. Also, the active metabolite of 
primaquine has safety issues in people with glucose-6-phosphate dehydrogenase 
deficiency leading to hemolytic anemia
174
. A new drug-screening study against 
Plasmodium showed that, 3 new agents in development: NPC1161B, OZ277 and 
methylene blue, reduce gametocyte viability by at least 50%
175
.  
Iron, an important element for the metabolism of all living organisms, has been 
considered as a target to treat malaria for the past few decades. Experimental evidence 
indicates a low molecular weight chelatable non-ferritin pool in erythrocytes, which 
provides bioavailable iron for Plasmodium
176
. Studies show the inhibition of parasites by 
iron chelators in mice and humans
176,177
. During gametocytogenesis, the tricarboxylic 
acid cycle becomes more active
178,179
 mainly to produce succinyl Co-A for heme 
biosynthesis instead of the full oxidation of glucose
180
. In P. falciparum, cytochrome b, 
which binds two heme molecule groups, has an increased expression of several fold in 
sexual stages compared to asexual stages
181
. In addition, mRNAs of three of the six genes 
involved in heme biosynthesis are upregulated during gametocytogenesis
182
.  
Plasmodium growth in culture is  inhibited by iron chelators, with a greater effect 
on the trophozoite stage
184,98
. In addition, iron chelators inhibit liver stage malaria and 
iron supplementation increases the number of merozoites released from the liver
176
. 
Therefore, iron chelation and iron deficiency can inhibit Plasmodium growth in vivo.  
FBS0701 is a new iron chelator that recently completed a Phase 2 clinical trial to 
treat transfusional iron overload
111
. FBS0701 can be administered as a single daily dose 
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because of its favorable absorption and pharmacokinetic properties compared to the other 
iron chelators- deferoxamine and deferiprone
110
. FBS0701 was recently shown to inhibit 
early gametocyte stages
158
. Although iron chelation is a good strategy to target malaria 
there is need for the development of a more suitable and safer drug.  
In general, the metabolism of Plasmodium gametocytes and especially their iron 
requirements have not been explored in detail. In this study, we tested the activity of 
FBS0701 as a potential transmission-blocking drug on P. falciparum sexual stages.  
 
4.3  METHODS  
4.3.1  Materials  
 FBS0701 was obtained from Aptuit, Kansas City, LLC under good manufacturing 
practice. P. falciparum NF54 cultures were obtained from Johns Hopkins School of 
Public Health Core Facility. 
 
4.3.2  Drug treatment 
 Drug assays were performed in 6-well plates by adding dilutions of FBS0701 (3 
µM - 100 µM) and deferoxamine (DFO) (Sigma, St. Louis, MO) at 12.5 µM and 25 µM. 
Drugs were added to fifteen day old P. falciparum NF54W gametocytes which are 
considered late stage. Cultures were maintained in complete RPMI-1640 with glutamine 
(Corning cell gro, Manassas, VA), along with HEPES, 10% human serum and 50 mg/ml 
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hypoxanthine without antibiotics. Parasitemia was maintained at 2.5% and 4% hematocrit 
in a gassed jar (5%O2, 5% CO2 and 90% N2) at 37ºC for 24, 48h or 72h. Control parasites 
were incubated with complete RPMI media without antibiotics. Medium was replaced 
daily with new FBS0701 diluted in RPMI without the addition of erythrocytes. 
 The same methodology was followed to incubate cultures with ferric chloride at 
2.5 µM, 12.5 µM and 50 µM alone or in combination with FBS0701 at 25 µM for 24 h.    
 
4.3.3  Membrane feeding assays 
 Cultures were centrifuged at 108x g for 4 minutes. Pellets were resuspended with 
human serum and erythrocytes to a gametocytemia of 0.1% and 50% hematocrit. 
Gametocytes were fed to 6 day old sucrose-starved female An. gambiae mosquitoes 
through a membrane feeder (glass-made with an outer chamber for circulating 37ºC water 
and with a piece of parafilm covering the lower portion of the feeder).  
 After feeding, fed mosquitoes were sorted and maintained at 27ºC for 7 days until 
dissection of their midguts. Midguts were stained with 0.1% mercurochrome and oocyst 
number was used to evaluate the effect of drugs on the parasites.  
 
4.3.4  Exflagellation assays 
Ten microliters of the gametocyte culture from each treatment were pelleted and 
resuspended in 10 µl of exflagellation media (RPMI 1640 medium (Corning cell gro, 
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Manassas, VA) with 25 mM Hepes, 2 mM glutamine, 50 mg/ml hypoxanthine, 2 g 
sodium bicarbonate, 1 µM xanthurenic acid and 20% human serum). Exflagellation 
reactions were incubated for 15 minutes at room temperature and then loaded into an 
Improved Neubauer chamber (0.1 mm deep, Reichert, Buffalo, NY) for estimation of 





4.3.5  Viability assays  
 After incubation with FBS0701 at 25 µM for 48 h as described above, 100 µl of 
that culture were mixed with 10 µl of propidium iodide (PI) (100 ug/ml) (Sigma, St 
Louis, MO) and incubated for 10 min at 37ºC. Then 10 µl of the stained sample were 
pelleted by a quick spin at max speed and the pellet was resuspended with 10 µl of 37ºC 
1X PBS and placed immediately on a slide to be observed by fluorescent microscopy 
(Nikon upright 90i microscope). Viable gametocytes do not stain with PI while dead 
gametocytes become permeable and stain with PI. A total of 100 gametocytes were 







4.4  RESULTS 
4.4.1  FBS0701 affects P. falciparum gametocyte infectivity  
To analyze the effect of FBS0701 on P. falciparum gametocyte infectivity to 
mosquitoes, mature gametocytes were incubated with different concentrations of 
FBS0701 for 24, 48 and 72 hrs and then fed to An. gambiae mosquitoes. To measure 
gametocyte viability, oocyst numbers were determined on mosquito midguts dissected 7 
days post infection (dpi). We found a significant reduction in the number of oocysts that 
was dependent on the dose and time of incubation of P. falciparum gametocytes (p<0.001 
at 48 h and 72 h) (Figure 4.1A and B). A hundred percent of oocyst inhibition was found 
from a dose of 25 µM FBS0701 at 48 h (Figure 4.1C). The prevalence confirms the dose-
response pattern. We observed around 60% reduction in prevalence with a dose of 50 µM 
at 24 h and reduction of more than 80% with 25 µM at 48 h and 72 h (Figure 4.1D). Thin 
blood smears of the cultures before membrane feeding confirmed that gametocytes were 
actually present and morphologically intact before infecting the mosquitoes. We did not 
find large reduction in the number of gametocytes regardless of the incubation time or 

















































Figure 4.1: Incubation of P. falciparum gametocytes with FBS0701 inhibits development in the 
mosquito. To analyze the effect of FBS0701 (or FBS) on malaria gametocytes, P. falciparum mature 
gametocytes were incubated with different concentrations of FBS0701 for 12, 48 and 72 hours. 
Gametocytes were fed to An. gambiae mosquitoes and oocyst numbers were determined in mosquito 
midguts 7 days post infection. A-B.  Representative experiments. N= number of mosquitoes. Percent 
inhibition = [(mean oocyst # of control mosquitoes - mean oocyst # of experimental mosquitoes) / mean 
oocyst # of control mosquitoes] x 100. Prevalence = percentage of infected mosquitoes, Percentage 
reduction in prevalence = [(prevalence of control mosquitoes – prevalence of experimental mosquitoes) / 
prevalence of control mosquitoes] x 100. Significance of differences between the mean oocyst number of 
FBS0701 treatments compared to blank control were determined by One way Anova with Bonferroni's 
Multiple Comparison Test. C. Percent inhibition of oocyst formation. Bars represent the average % 
inhibition of oocyst formation from independent experiments shown in Table A1 (pooled data).  Error bars 
represent the standard error of the mean. D. Percent reduction in prevalence. Bars represent the average % 
reduction in prevalence (% infected mosquitoes) compared to the blank control, from independent 
experiments shown in Table A1 (pooled data). Error bars represent the standard error of the mean.  E. 
Percent of gametocytes present before membrane feeding.  Smears were made from each FBS0701 treated 
culture and gametocytes were counted by microscopy upon Giemsa staining. Data was obtained from one 














4.4.2  FBS0701 does not affect P. falciparum mosquito midgut stages 
 A method of testing if the drug was actually affecting mosquito stages was adding 
drug to the gametocyte cultures and proceed immediately to the membrane feeding 
without incubation. We found that FBS0701 does not affect mosquito stages revealed by 
non-significant difference in the oocyst number (Figure 4.2A). The highest percent of 
inhibition was obtained with a dose of 50 µM but did not surpass 60 %, whereas at that 
same concentration after 24 h of incubation we observed around 100% of oocyst 
inhibition (Figure 4.1B). Similarly, the reduction in prevalence at 50 µM was only around 

























Figure  4.2. FBS0701 does not affect Plasmodium sexual development in the mosquito midgut lumen. 
To analyze the effect FBS0701 (or FBS) on sexual stages of Plasmodium (gametes, zygotes and ookinetes), 
P. falciparum gametocytes were fed to An. gambiae mosquitoes in the presence of different concentrations 
of FBS0701. Oocyst numbers were determined in mosquito midgets 7 days post infection. A. 
Representative experiment. N= number of mosquitoes. Percent inhibition = [(mean oocyst # of control 
mosquitoes - mean oocyst # of experimental mosquitoes) / mean oocyst # of control mosquitoes] x 100. 
Prevalence = percentage of infected mosquitoes, Percentage reduction in prevalence = [(prevalence of 
control mosquitoes – prevalence of experimental mosquitoes) / prevalence of control mosquitoes] x 100. 
Significance of differences between the mean oocyst number of FBS0701 treatments compared to blank 
control were determined by One way Anova with Bonferroni's Multiple Comparison . NS= not significant. 
B. Percent inhibition of oocyst formation. Bars represent the average % inhibition of oocyst formation from 
independent experiments shown in Table A4 (pooled data). Error bars represent the standard error of the 
mean. C. Percent reduction in prevalence. Bars represent the average % reduction in prevalence (% 
infected mosquitoes) compared to the blank control, from independent experiments shown in Table A4 






4.4.3  Deferoxamine effects on mature P. falciparum gametocyte infectivity are 
milder compared to FBS0701  
 Next, we tested the effect of DFO, another iron chelator known to have 
antimalarial activity against P. falciparum. We used 12.5 µM and 25 µM and the same 
incubation times as for FBS0701. We found that DFO induces a significant oocyst 
decrease (p< 0.05 and p< 0.001 at 48 h and 72 h respectively) in a similar dose response 
behavior as FBS0701 (Figure 4.3A). However, the percent of oocyst inhibition never 
reached to 100 even at 25 µM after 72 h (Figure 4.3B).  The highest reduction in 


















Figure 4.3: Incubation of P. falciparum gametocytes with DFO inhibits development in the mosquito 
to a lesser extent. To analyze the effect of DFO on malaria gametocytes, P. falciparum mature 
gametocytes were incubated with different concentrations of FBS0701 for 12, 48 and 72 hours. 
Gametocytes were fed to An. gambiae mosquitoes and oocyst numbers were determined in mosquito 
midguts 7 days post infection. A. Representative experiment. N= number of mosquitoes. Percent inhibition 
= [(mean oocyst # of control mosquitoes - mean oocyst # of experimental mosquitoes) / mean oocyst # of 
control mosquitoes] x 100. Prevalence = percentage of infected mosquitoes, Percentage reduction in 
prevalence = [(prevalence of control mosquitoes – prevalence of experimental mosquitoes) / prevalence of 
control mosquitoes] x 100. Significance of differences between the mean oocyst number of FBS0701 
treatments compared to blank control were determined by One way Anova with Bonferroni's Multiple 
Comparison Test. B. Percent inhibition of oocyst formation. Bars represent the average % inhibition of 
oocyst formation from independent experiments shown in Table A2 (pooled data).  Error bars represent the 
standard error of the mean. C. Percent reduction in prevalence. Bars represent the average % reduction in 
prevalence (% infected mosquitoes) compared to the blank control, from independent experiments shown 







4.4.4  Iron blocks FBS0701 and restores gametocyte fertility 
 The loss of fertility of P. falciparum gametocytes incubated with FBS0701 is 
presumably induced by iron chelation. To test this hypothesis, FBS0701 (25 µM) was pre 
incubated with FeCl3 (12.5, 25, or 50 µM) and then added to the gametocyte culture. 
Gametocytes were cultured with the FBS0701/FeCl3 mixture for 24 hrs, fed to 
mosquitoes and oocyst numbers were determined 7 days post infection. The results 
showed that when the drug is pre incubated with FeCl3 the oocyst number is considerably 
higher compared to the FBS0701 treated culture. Individual iron supplementations 
showed negative effects on oocyst number although they were not as high in numbers 
compared to their respective counterparts in the combinations Fe-FBS0701 (Figure 
4.4A). As can be seen on figure 4.4B, FBS0701 at 25 µM induced an oocyst inhibition 
higher than 80% whereas FBS0701-Fe showed 0% in oocyst inhibition relative to the 
effect seen with FBS0701 25µM (Figure 4.4B). The reduction in prevalence was around 
50% for cultures treated with FBS0701 whereas those treated with FBS0701-Fe or iron 


















Figure 4.4: Iron restores infectivity to P. falciparum gametocytes incubated with FBS0701. To 
determine if the inhibitory effect of FBS0701 (or FBS) on gametocytes infectivity was due to iron 
chelation, FBS0701 was pre incubated with different concentrations of Fe before adding it to the 
gametocyte culture. Gametocytes were incubated with FBS0701/Fe for 24 hrs and then fed to An. gambiae 
mosquitoes. Oocyst numbers were determined in mosquito midguts 7 days post infection. A. 
Representative experiment. N= number of mosquitoes. Percent inhibition = [(mean oocyst # of control 
mosquitoes - mean oocyst # of experimental mosquitoes) / mean oocyst # of control mosquitoes] x 100. 
Prevalence = percentage of infected mosquitoes, Percentage reduction in prevalence = [(prevalence of 
control mosquitoes – prevalence of experimental mosquitoes) / prevalence of control mosquitoes] x 100. 
Significance of differences between the mean oocyst number of FBS0701 treatments compared to blank 
control were determined by One way Anova with Bonferroni's Multiple Comparison Test. NS= not 
significant. B. Percent inhibition of oocyst formation. Bars represent the average % inhibition of oocyst 
formation from independent experiments shown in Table A3 (pooled data).  Error bars represent the 
standard error of the mean. C. Percent reduction in prevalence. Bars represent the average % reduction in 
prevalence (% infected mosquitoes) compared to the blank control, from independent experiments shown 








4.4.5  Mature P. falciparum gametocytes treated with FBS0701 show decreased 
numbers of exflagellations  
 The reduction in oocyst numbers detected after gametocyte treatment with 
FBS0701 could result from a failure of gametocyte activation into gametes or a failure of 
development into the subsequent mosquito midgut stages (zygotes, ookinetes and 
oocysts). Gametocyte activation into gametes is the first step of parasite development in 
the mosquito midgut lumen and can be measured by quantifying the number of male 
gamete exflagellations.  To determine if FBS0701 treatment inhibits gametocyte 
activation, male gamete exflagellations were measured in gametocyte cultures incubated 
in the presence (25 µM) or absence of FBS0701 for 48 hrs. We did not find 
exflagellations on the FBS0701 treated gametocyte culture (Figure 4.5) compared to 


















Figure 4.5. FBS0701 at 25 µM for 48 h decreases (inhibits) exflagellation centers. FBS0701 (or FBS) 
treated mature gametocytes were activated with exflagellation media containing 1 uM xanthurenic acid and 
incubated at room temperature. Exflagellation centers were counted 15 min post activation and observed at 
40 X (Olympus BX53 microscope) in duplicates. Results are presented as the numbers of exflagellation 
centers per 10
6











4.4.6  FBS0701 kills mature P. falciparum gametocytes  
 A reduction in male exflagellations after treatment with FBS0701 could result 
from inhibition of gamete activation or gametocyte killing induced by the drug. To test 
this hypothesis, the membrane impermeant propidium iodide (PI) fluorescent molecule 
was used for life/dead staining of gametocytes incubated with FBS0701. Only dead cells 
stain with PI as their membrane become permeable and the dye gain access to the DNA 
and RNA of the cell. A significant reduction in live gametocytes was observed for 
gametocytes treated with 25 µM for 48 hrs of FBS0701 (95 live and 5 dead) compared to 
























Figure 4.6. FBS0701 at 25 µM for 48 h kills fifteen day old P. falciparum gametocytes. FBS0701 
treated gametocytes were incubated with 10 µl propidium iodide (PI) (100 ug/ml) and incubated for 10 
min. After pelleting, the culture was resuspended in 1X PBS. Fluorescent microscopy imaging showing 
representative gametocytes from 25 µM FBS0701 treated (A-B) and non treated cultures (C-D) after 48 
hours. Gametocytes are observed within the yellow circles. A and C. Pictures on phase 3 (red). B and D. 










4.5  DISCUSSION 
 As discussed in other studies the antimalarial properties of iron chelators are 
known
25
. The new iron chelator FBS0701 was found to have antimalarial properties in 
the Plasmodium blood stages in vitro and in vivo
158
. FBS0701 was not able to affect late 
gametocyte stages when examined by blood film.  Anopheles gambiae mosquitoes 
conserve iron absorption proteins and intracellular iron utilization proteins identical to the 
proteins in mammals
185
. Once iron is ingested in the blood meal it has to be transported to 
the ovaries for egg development. For the vector host, iron is an important element for 
producing offspring but not for individual survival. After all, male and female mosquitoes 
can survive individually mainly from a sugar source. From this point, is it understandable 
that the FBS0701 action might be null. The parasite would readapt its metabolism in the 
new host and take advantage of the nutrients and elements abundant and/or important for 
the host itself.     
 In a previous publication, FBS0701 was found to be effective predominantly on 
early stage gametocytes (around 90% inhibition) versus late stage gametocytes (around 
50% inhibition) under the same dose of 100 µM
158
. Here we demonstrated that even 
when late stage gametocytes are treated with FBS0701 we could induce a significant 
decrease in oocysts after an artificial mosquito feeding.  Now with the evidence of a 
partial inhibition on late stages from the past study by Ferrer et al.
158
 and our results on 
oocyst reduction we considered two possibilities: remaining gametocytes after treatment 
could have their exflagellation impaired or they could be already dead before the 
membrane feeding.  We confirmed that FBS0701 treated gametocytes had lower number 
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of exflagellation centers but this is the result of a smaller living population in the treated 
cultures. The propidium iodide confirmed that those gametocytes present counted by light 
microscopy before the membrane feeding were already dead.    
 In the study by Ferrer et al. 
158
, it was confirmed that FBS0701 could chelate and 
remove intracellular iron, whereas the antimalarial deferoxamine, a lipophobic iron 
chelator, may not access and chelate intracellular iron with effectiveness. This would 
explain the higher inhibition of oocyst formation under FBS0701 treatment compared to 
deferoxamine.   
 We were able to confirm that the decrease in oocyst numbers was because of 
FBS0701 action, when we blocked the drug with ferric chloride the chelating activity was 
suppressed allowing more oocysts to be formed in the mosquito midguts. 
 The mitochondria of Plasmodium asexual stages and early gametocytes have few 
cristae. Stages III, IV and V macrogametocyte show an increase in cristae mitochondria 
but microgametes have fewer mitochondria
178,186
. There is also an increased expression of 
the heme binding protein cytochrome b in sexual stages
181,187
. The tricarboxilic acid 
would be more active during sexual stages to produce succinyl Co-A for heme 
biosynthesis. However, it is also suggested that sexual parasites could have an 
underdeveloped metabolically active TCA cycle for respiration
178,179
. 
 Besides energy production, the electron transport system can also be used for 
pyrimidine biosynthesis. It is suggested that the mitochondrial activity seen in the sexual 
stages is meant to fulfill this goal. De novo pyrimidine synthesis in early gametocytes 
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would be enough for the sustainment of the maturation process
168,188
. So the question is 
how can an iron chelator induce parasite death by removing an element that apparently is 
not indispensible especially for late stage gametocytes? Early gametocytes do not 
replicate their DNA so we discard the possibility of FBS0701 interfering with DNA 
replication by depriving ribonucleotide reductase from iron. We hypothesize that 
FBS0701 can exert a toxic mechanism or interfere with the energy production system 
which can still work on gametocytes; after all, protein components of the electron 

































Iron is important for all living organisms and we demonstrated here that it is also 
important for Plasmodium development. Our first purpose was to understand the 
importance of iron compartmentalization and bioavailability from the host cells for the 
blood and liver stages of the parasite life cycle. Second, evaluate the parasitic need for 
bioavailable iron within the hepcidin – iron – infection axis in a context of iron deficient 
anemia and non anemia and iron supplementations.         
The fight against malaria is difficult because of the development of resistant 
Plasmodium strains. Identification of a target not prone to amino acid mutation is 
important. Iron chelators have proven to be a good alternative to circumvent mutations on 
their non mutable drug target-iron. However, their use has been limited because of 
unsuitable pharmacokinetic properties. FBS0701 was designed to treat transfusional iron 
overload and when we obtained the drug for our studies it was under current Phase 2 
human studies. Before our research began, we were aware of the advantages of this drug: 
its favorable absorption, high affinity for ferric iron and pharmacokinetics properties all 
of which allowed single daily dose to be effective
109,110
.  
We proved that FBS0701 can effectively sequester and remove intracellular iron 
from the erythrocyte consequently inhibiting the development of the parasite on blood 
stages. The fact that FBS0701 also affects the liver stage, led us think that FBS0701 also 
deprived intracellular hepatic iron. Iron removal is a distinctive characteristic compared 
to other drugs since it may not only be the cause of its action but also allows the drug to 
be effective even after its clearance from plasma (post-drug effect). Early studies 
suggested that iron chelators interfere especially on replicating stages of Plasmodium 
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(interfering with the DNA replication)
189,184,98
. According to this idea, iron chelators 
should have a higher effect on the late trophozoites. We found that upon continuous 
cultures starting at specific parasite stages, the IC50 for FBS0701 was 6 µM for rings and 
trophozoites, although 15 µM for schizonts which is past point of DNA replication. 
Chelation by FBS0701 is stage and concentration dependent. On our initial studies on 
gametocytes we observed that early stages were more affected (decreased numbers) 
compared to late stages that were morphologically intact by Giemsa film. Although early 
gametocytes do not replicate DNA, they are very similar metabolically to asexual 
stages
132
. Later we studied the effect of FBS0701 on 15 –day old P. falciparum 
gametocytes and evaluated the effect by the numbers of oocyst forming in mosquito 
midguts after membrane feeding. We found a decrease in the number and prevalence of 
oocysts after drug treatment of gametocytes. We even found that FBS0701 was more 
effective than DFO. This finding led us reconsider if FBS0701 was really inhibiting the 
DNA replication only. After staining treated gametocytes with propidium iodide we 
confirmed that parasites were killed by the drug and therefore reduced effective number 
of oocysts to near zero with microM concentrations of FBS0701. By microscopy, the 
morphology of gametocytes is intact. We think that the mechanism of action of iron 
chelators may be related to interference with DNA replication in asexual stages and even 
on hepatic stages but it could change to or simultaneously be toxic by interfering with the 
cellular energy system. Sexual stages have increased expression of proteins involved 
electron transport reactions. Cytochromes in the electron transport chain contain a heme 





Our studies suggest the FBS0701 can be used in combinatory therapy with 
chloroquine, quinine (both found in vitro) and primaquine (found in vivo). Unfortunately, 
we found interference with artemisinin. Because the drug has a prolonged effect even 
after being fully metabolized in the liver, FBS0701 could be used as prophylactic or in 
combination with other antimalarials during the treatment of a current infection. 
FBS0701 may perturb an iron compartment on the circulating erythrocyte that may not be 
restored until the formation of new red blood cells. We demonstrated that we can have 
complete cure on mice receiving a single oral dose one day post infection. Some concern 
is raised about the use of iron chelators to treat malaria since most populations at risk of 
infection suffer from iron deficient anemia; this concern is even higher for anemic 
children. Based on the pharmacodynamics of the drug, FBS0701 at 32 mg/kg would not 
remove more than 20 mg of iron from the host over 24 h, considering that normal iron 
body stores range around 2-6 g. This amount should not affect total iron status in a short 
3-5 day treatment regimen for malaria.       
One advantage that we found about FBS0701 as antimalarial is that it targets 
more than one single stage of malaria. This makes the iron chelator attractive for 
elimination strategies. Although we proved that it does not interfere directly with 
mosquito stages, but may contribute to block the transmission of viable gametocytes to 
the mosquito. An additional study would be to test the effect of parasite development on 
mosquito stages after feeding the vectors on infected FBS0701 treated mice. Also, if 
resistance was to emerge, the mechanism or resistance would likely be different from 
other antimalarial drug resistance mechanisms. The action of FBS0701 is mainly due to 
sequestration of iron.  
134 
 
Our studies on iron diets, phlebotomized anemic mice, transgenic anemic mice, 
and non-anemic mice evaluated parasite development on different settings of hepatic 
iron. We confirmed the importance of iron compartmentalization with the hepcidin 
transgenic mice (low iron on hepatocytes) and hemoglobin deficient mice (or hbd, defect 
on erythroid progenitor cells but with unchanged hepatocyte iron stores). The hepcidin 
transgenic mice developed more pronounced liver stage malaria compared to the hbd 
mice. There are some questions that we have not addressed here: a) the blood stage 
infection on transgenic mice, though we speculate that malaria liver stages would be 
more pronounced compared to the blood stage and b) the effect of iron supplementation 
on hbd at both the hepatic and blood stages. We would expect to see a protection from 
severe disease caused by a blood stage and similar effects on the liver stages as the ones 
we have just reported in our study, in other words, high levels of parasite loads in the 
liver.     
There are contradictory results about the negative or null effect of iron 
supplementation on malaria risks
118,119,120,143,146
. Our work tried to replicate the Pemba 
trial although we did not give folate supplementation simultaneously as on the African 
study
112
.  We used the same hematologic biomarkers as on Pemba: hemoglobin and 
ZnPPIX , though we are aware that sometimes the use of different parameters, e.g. 
ferritin saturation, has led to contradictory results
190
. However, we obtained similar 
results to the Pemba trial. Our findings tell us that iron replete individuals after iron 
supplementation increase their hepatic parasite load. Also, in the hepcidin -iron – 
infection axis the dominant regulator may vary with time. Hepcidin could predominate at 
the beginning but iron would be dominant regulator over time. We are also considering a 
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change on hepatocyte ferroportin responsiveness in the context of anemia and iron 
supplementation. In areas where malaria is endemic and people are under constant 
infections or superinfections, malaria contributes to anemia, and hepcidin can also be 
increased by malaria infection by unknown mechanisms. These contexts refer to blood 
stages of malaria while we only tested the effect on liver stage.  It would be interesting 
for future research to repeat the experiment adding an antimalarial such as primaquine 
along with iron supplementation and see the effect on hepatic parasite load. A previous 
study found that an ongoing blood stage infection treated with antimalarials did not 
preclude the hepatic development of a secondary infection in the context of a 
superinfection
9
. This was the result of the reduction in hepcidin expression because the 
blood stage parasitemia diminished or was cured. On a repetition of our experiment we 
would expect to see no difference in the parasite load between anemic and non-anemic 
mice under an ongoing antimalarial treatment and iron supplementation. We only tested 
the effect with one type of iron supplementation (iron diet) but future studies could also 
explore the difference in type or iron supplementation: e.g. intraperitonael iron dextran 
and blood transfusion. Blood stage parasitemia interferes with the use of iron from the 
host. We believe that our findings support the idea that iron status influences malaria 
risks and that iron supplementation can be positive for parasite development in the liver 
(site of the beginning of the infection); especially when the liver iron stores are replete. 
Policies of iron supplementation in malaria endemic and iron deficient areas should 
include antimalarial treatment and surveillance simultaneously. However, it is important 
for the iron supplementation policies to consider that malaria endemic areas overlap with 
iron deficiency anemia, and also overlap with other infectious diseases. Iron is important 
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for all living organisms, and the availability of the metal can regulate the susceptibility to 
other non-malaria infectious diseases. Upon iron supplementation studies have shown to 
increase cases of malaria, brucellosis and schistosomiasis
119
. We have not tested 
FBS0701 on other organisms but it could also be useful to target more than one 
microorganism at a time.     
In summary (diagram below), we have confirmed that Plasmodium development 
requires iron. We believe it can be used for DNA replication or the function of electron 
transporter chain for energy production. The new iron chelator FBS0701 can sequester 
and remove intercellular iron from erythrocytes decreasing the development of asexual 
and sexual stages. Similar mechanisms may occur in the hepatic stage; we observed a 
reduction of parasite load in the liver upon murine infection. FBS0701 could even have 
the potential as a transmission blocking agent by killing mature stage gametocytes. 
FBS0701 could be used as part of a combination therapy with drugs that target any stage 
of the parasite except with artemisinin. We have also confirmed that iron 
supplementation increase parasite loads on hepatic stages in the context of non-anemia. 
Policies on iron supplementation in malaria endemic areas should be implemented along 







Erythrocytic stage inhibited by: 
- Iron chelator FBS0701  
FBS0701 effect on erythrocytic stage: 
- IC50 stage specific and lower 
compared to deferoxamine and 
deferiprone 
- Additive action with chloroquine and 
quinine 
- Confines infection to reticulocytes in a 
P. yoellii infection and cures infected 
mice   
-  Chelates and removes intracellular 
iron  
Liver stage decreased by: 
- Iron chelator FBS0701 
- Synergistic action between FBS0701 and 
primaquine 
- Redistribution of iron 
(compartmentalization) after hepcidin 
expression 
- High levels of hepcidin 
Liver stage increased by: 
- Low levels of hepcidin  
- Iron supplementation in iron replete mice 
(non-anemic, non iron deficient) 
- Predominance of iron supplementation 
over a negative hepcidin effect 
Early sexual stage (early gametocytes) numbers reduced by: 
- Iron chelator FBS0701 
Late sexual stage (late gametocytes) killed by: 
- Iron chelator FBS0701   
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Table A1:  Effect of incubation of P. falciparum mature gametocytes with FBS0701 
on mosquito stage development. P. falciparum mature gametocytes were incubated with 
different FBS (FBS0701) concentrations for 14, 48 and 72 hrs. and then fed to An. 
gambiae female mosquitoes. Oocyst numbers were determined on mosquito midguts 
dissected 7 days post infection. N= number of mosquitoes, prevalence= % of infected 
mosquitoes, percent inhibition = ([mean or median oocyst # for control mosquitoes - 
mean or median oocyst # for experimental mosquitoes] / mean or median oocyst # for 
control mosquitoes) X 100. Statistical significance was determined by Mann Whitney U 





Experiment Treatment Period (hrs) uM N Prevalence Mean oocyst # (Range) % inhibition P-value
Blank 24 0 35 97.1 90.6 (0-302) - -
FBS 24 12.5 29 100 85.0 (23-204) 6.19 NS
FBS 24 25 40 87.5 17.8 (0-48) 80.4 <0.001
Blank 48 0 35 94.3 41.5 (0-129) - -
FBS 48 12.5 32 87.5 16.2 (0-50) 61 <0.001
FBS 48 25 28 10.7 0.11 (0-1) 99.7 <0.001
Blank 72 0 30 63.3 35.4 (0-116) - -
FBS 72 12.5 27 14.8 0.19 (0-2) 99.5 <0.001
FBS 72 25 18 0 0 (0) 100 <0.001
Blank 24 0 45 93.3 34.6 (0-116) - -
FBS 24 25 48 52.1 1.3 (0-9) 96.2 <0.001
FBS 24 50 45 26.7 0.73 (0-9) 97.9 <0.001
Blank 48 0 40 87.5 32.1 (0-107) - -
FBS 48 25 41 17.1 0.17 (0-1) 99.5 <0.001
FBS 48 50 45 6.7 0.07 (0-1) 99.8 <0.001
Blank 72 0 39 61.5 10.1 (0-56) - -
FBS 72 25 42 4.8 0.07 (0-2) 99.3 <0.001
FBS 72 50 37 5.4 0.05 (0-1) 99.5 <0.001
Blank 48 0 39 79.5 48.2 (0-172) - -
FBS 48 12.5 40 82.5 23.0 (0-60) 52.3 <0.001
FBS 48 25 49 8.2 0.14 (0-4) 99.7 <0.001
Blank 72 0 38 76.3 29.4 (0-104) - -
FBS 72 12.5 43 44.2 1.28 (0-10) 95.6 <0.001
Blank 24 0 29 67.1 3.1 (0-16) - -
FBS 24 25 32 9.4 0.13 (0-2) 96 <0.001









Table A2:  Effect of incubation of P. falciparum mature gametocytes with DFO on 
mosquito stage development. P. falciparum mature gametocytes were incubated with 
different FBS (FBS0701) concentrations for 14, 48 and 72 hrs. and then fed to An. 
gambiae female mosquitoes. Oocyst numbers were determined on mosquito midguts 
dissected 7 days post infection. N= number of mosquitoes, prevalence= % of infected 
mosquitoes, percent inhibition = ([mean or median oocyst # for control mosquitoes - 
mean or median oocyst # for experimental mosquitoes] / mean or median oocyst # for 
control mosquitoes) X 100. Statistical significance was determined by Mann Whitney U 







Experiment Treatment Period (hrs) uM N Prevalence Mean oocyst # (Range) % inhibition P-value
Blank 24 0 52 75 25.3 (0-115) - -
DFO 24 12.5 45 71.1 17.6 (0-90) 30.6 NS
DFO 24 25 38 78 18.1 (0-93) 28.3 NS
Blank 48 0 43 53.5 24.1 (0-124) - -
DFO 48 12.5 39 61.5 23.2 (0-89) 3.7 NS
DFO 48 25 50 42 12.7 (0-98) 47.2 NS
Blank 72 0 43 55.8 26.1 (0-112) - -
DFO 72 12.5 45 55.6 20.6 (0-122) 21.1 NS
DFO 72 25 39 48.7 10.7 (0-45) 59 NS
Blank 24 0 37 78.4 13.7 (0-66) - -
DFO 24 12.5 45 86.7 9.36 (0-62) 31.7 NS
DFO 24 25 42 83.3 14.1 (0-34) 0 NS
Blank 48 0 50 92 7.94 (0-31) - -
DFO 48 12.5 46 73.9 7.57 (0-37) 4.72 NS
DFO 48 25 32 65.6 3.41 (0-18) 57.1 < 0.05
Blank 72 0 32 81.3 9.06 (0-31) - -
DFO 72 12.5 37 59.5 2.76 (0-16) 69.6 < 0.001
DFO 72 25 42 27.9 0.72 (0-6) 92 < 0.001
Blank 24 0 22 90.9 18.5 (0-90) - -
DFO 24 12.5 23 95.7 24.2 (0-62) 0 NS
DFO 24 25 23 82.6 24.9 (0-97) 0 NS
Blank 48 0 27 85.2 16.0 (0-53) - -
DFO 48 12.5 26 73.1 15.9 (0-61) 0.49 NS












Table A3:  Effect of incubation of P. falciparum mature gametocytes with FBS0701 
and Fe on mosquito stage development. FBS (FBS0701) was incubated with different 
concentrations of Fe before adding it to the P. falciparum gametocytes. Gametocytes 
were incubated with FBS and or Fe for 24 hrs and then fed to An. gambiae female 
mosquitoes. Oocyst numbers were determined on mosquito midguts dissected 7 days post 
infection. N= number of mosquitoes, prevalence= % of infected mosquitoes, percent 
inhibition = ([mean or median oocyst # for control mosquitoes - mean or median oocyst # 
for experimental mosquitoes] / mean or median oocyst # for control mosquitoes) X 100. 








Experiment Treatment Period (hrs) uM N Prevalence Mean oocyst # (Range) % inhibition P-value
Blank 24 0/0 41 87.8 34.9 (0-127) - -
FBS/Fe 24 25/12.5 37 97.3 57.8 (0-115) 0 < 0.01
FBS/Fe 24 25/25 48 97.3 44.3 (0-131) 0 < 0.05
FBS/Fe 24 25/50 55 98.2 40.1 (0-102) 0 NS
Fe 24 0/12.5 40 97.5 38.0 (0-120) 0 NS
Fe 24 0/25 39 92.3 20.9 (0-65) 40.2 NS
Fe 24 0/50 40 85 17.5 (0-70) 50 NS
Blank 24 0/0 67 92.5 14.3 (0-36) - -
FBS 24 25/0 57 12.3 0.16 (0-3) 98.9 < 0.001
FBS/Fe 24 25/12.5 54 88.9 17.2 (0-53) 0 NS
FBS/Fe 24 25/25 61 95.1 25.7 (0-68) 0 < 0.001
FBS/Fe 24 25/50 65 96.9 19.3 (0-92) 0 NS
Fe 24 0/12.5 52 84.6 10.5 (0-49) 26.9 NS
Fe 24 0/25 39 97.4 11.8 (0-28) 17.8 NS
Fe 24 0/50 42 92.9 11.6 (0-41) 19.2 NS
Blank 24 0/0 43 88.4 54.7 (0-197) - -
FBS 24 25/0 39 74.4 9.05 (0-29) 83.4 < 0.01
FBS/Fe 24 25/12.5 42 83.3 55.6 (0-241) 0 NS
FBS/Fe 24 25/25 43 86.1 65.2 (0-283) 0 NS
FBS/Fe 24 25/50 39 79.5 71.6 (0-227) 0 NS
Fe 24 0/12.5 33 84.9 23.6 (0-118) 56.8 NS
Fe 24 0/25 39 84.6 31.1 (0-161) 43.2 NS











Table A4:  Effect of FBS0701 on P. falciparum sexual reproduction inside the 
mosquito midgut. P. falciparum gametocytes cultures were fed to An. gambiae 
mosquitoes in the presence of different concentrations of FBS (without previous 
preincubation with the drug). Oocyst numbers were determined on mosquito midguts 
dissected 7 days post infection. N= number of mosquitoes, prevalence= % of infected 
mosquitoes, percent inhibition = ([mean or median oocyst # for control mosquitoes - 
mean or median oocyst # for experimental mosquitoes] / mean or median oocyst # for 
control mosquitoes) X 100. Statistical significance was determined by Mann Whitney U 













Experiment Treatment uM N Prevalence Mean oocyst # (Range) % inhibition P-value
Blank 0 38 92.1 34.6 (0-152) - -
FBS 3.38 37 100 30.5 (0-116) 11.8 NS
FBS 6.75 39 87.2 24.9 (0-139) 28.0 NS
FBS 12.5 42 97.6 27.0 (0-149) 22.0 NS
FBS 25 44 93.2 26.8 (0-117) 22.7 NS
FBS 50 43 76.7 16.5 (0-69) 52.4 NS
FBS 100 37 94.6 21.6 (0-116) 37.4 NS
Blank 0 13 100 73.0 (8-207) - -
FBS 12.5 10 100 87.6 (25-192) 0 NS
FBS 25 9 100 53.8 (11-95) 26.3 NS
FBS 50 25 92 42.0 (0-90) 42.5 NS
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2010 - 2014 
 
PhD candidate, JOHNS HOPKINS MALARIA REASEARCH 
INSTITUTE, JOHNS HOPKINS SCHOOL BLOOMBERG SCHOOL OF 
PUBLIC HEALTH, Baltimore - USA 
 
PROJECT: Characterization of the antimalarial pharmacodynamics of the 
novel iron chelator FBS0701. 
 
GOALS:  
1. To identify the FBS0701 effective dose, timing and duration of 
antimalarial action in vivo and the IC50 and mechanism of action in 
vitro. 
2. To characterize the interaction of FBS0701 with other antimalarials on 
blood and hepatic stages in vitro and in vivo. 
3. To test the activity of FBS0701 on mosquito stages previous treatment 
of P. falciparum gametocytes. 
 
PERFORMED THE FOLLOWING ASSAYS:  
 Drug sensitivity assay with SYBR Green. 
 Giemsa staining and counting of Plasmodium infected erythrocytes 
by microscopy.  
 Murine drug testing after oral gavage and intraperitoneal 
Plasmodium infected erythrocytes.  
 Blood collection by murine cardiac puncture. 
 Cloning of plasmids for Real Time PCR quantification.  
 Murine liver harvest and homogenization of livers with TRizol. 
 Phenol-chloroform RNA isolation and Real Time PCR 
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quantification of parasite infection and gene expression.  
 Salivary gland dissection of Plasmodium infected mosquitoes and 
sporozoite infection by tail vein injection of mice.  
 Mosquito membrane feeding after drug testing of Plasmodium 
gametocyte cultures.  
 Midgut dissection of Plasmodium infected mosquitoes and 
counting of mercurochrome-stained oocysts by microscopy.  
 Exflagellation assays and viability determination by propidium 
iodide staining of drug treated Plasmodium gametocytes. 
 
 
2010 - 2014 
 
PhD candidate, JOHNS HOPKINS MALARIA REASEARCH 
INSTITUTE, JOHNS HOPKINS SCHOOL BLOOMBERG SCHOOL OF 
PUBLIC HEALTH, Balimore - USA 
 
PROJECT: Evaluation of the effect of low and rich iron diets on murine 
malaria infection during iron repletion with implications for human 




1. To compare the effect of a low, normal and high iron diet given for two 
weeks versus six weeks on hepatic malaria infection in iron replete mice 
and iron deficient mice. 
2. To evaluate the level of hepatic malaria infection on transgenic 
overexpressing hepcidin (Tg+) mice upon the addition of exogenous 
hepcidin and on hemoglobin deficient mice (hbd).  
3. To correlate malaria hepatic outcomes with the level of the iron 
regulatory hormone hepcidin in genotypic anemic mice, anemic non-
genotypic mice and iron replete mice.  
 
PERFORMED THE FOLLOWING ASSAYS:  
 Murine phlebotomy by facial bleeding and eye bleeding. 
 Murine liver harvest and homogenization of livers with TRizol. 
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 Phenol-chloroform RNA isolation and Real Time PCR 
quantification of parasite infection and gene expression.  
 Salivary gland dissection of Plasmodium infected mosquitoes and 
sporozoite infection by tail vein injection of mice.  
 Determination of anemia and iron deficiency by: hemoglobin 
estimation with Drabkin solution, ZnPPIX/heme measurement and 
haematocrit quantification. 
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UNIVERSIDAD PERUANA CAYETANO HEREDIA, Lima - Peru 
 
PROJECT: Determination of pncA mRNA expression level in MTB 
isolates trough real time PCR. 
 
GOAL: To study the relationship between the expression levels of pncA 
gene and the PZA resistance levels and enzymatic efficiency in mutant 
strains. 
 
Performed mRNA quantification through real time PCR. 
 
 
2006 - 2008 
 
Research Associate, INFECTIOUS DISEASES LABORATORY – LID,  
UNIVERSIDAD PERUANA CAYETANO HEREDIA, Lima - Peru 
 
NIH Grant to PS (5-R03-AI-067608-02). - “Towards tuberculosis control: 
pyrazinamide susceptibility and resistant mechanism”  
 
PROJECT: Relationship between Pyrazinamidase susceptibility and 
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Pyrazinamidase kinetic parameters in Mycobacterium tuberculosis 
 
GOAL: To study the relationship between the enzymatic activity of 
recombinant Pyrazinamidases mutants bearing a single amino acid 
substitution with the microbiological pyrazinamamide susceptibility in 
their respective clinical isolates and the location of the mutation. 
 
PERFORMED THE FOLLOWING ASSAYS:  
 Selection of M. tuberculosis sputum isolates through Wayne test. 
 Cloning of the M. tuberculosis pncA gene from mutant strains as 
well as from the wild type H37Rv reference strain. 
 Expression and purification of the recombinant PZAases using 
affinity chromatography and SDS PAGE visualization. 
 Measurement of PZA susceptibility parameters of the clinical 
isolates using Bactec 460TB, culture MIC and Wayne activity 
 Measurement of kinetic parameters using Wayne activity 
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UNIVERSIDAD PERUANA CAYETANO HEREDIA 
 
NIH Grant to PS (5-R03-AI-067608-02). - “Towards tuberculosis control: 
pyrazinamide susceptibility and resistant mechanism”  
 
PROJECT: Effect of metals ions on the reactivation of Pyrazinamidase 
enzyme in Mycobacterium tuberculosis 
 
GOALS: 
1. To standardize the chelation method to inactivate the enzyme. 
2. To identify the optimal concentrations on ions, through titration, to 
reactivate the    chelated H37Rv Pyrazinamidase. 
3. To determine the recovery activity percentages of chelated 
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Pyrazinamidase with the optimal concentrations of the ions. 
4. To assess the consequences of an ionic interaction on enzymatic 
activity. 
5. To determine the variation of chelated Pyrazinamidase enzyme kinetic 
parameters on the presence of different ions independently. 
 
PERFORMED THE FOLLOWING ASSAYS:  
 Cloning of the M. tuberculosis pncA gene from mutant strains as 
well as from the wild type H37Rv reference strain. 
 Expression and purification of the recombinant PZAases using 
affinity chromatography and SDS PAGE visualization. 
 Measurement of kinetic parameters using Wayne activity. 
 Inactivation of Pyrazinamidase by depletion of metals using EDTA. 





Research Associate, MOLECULAR NEUROBIOLOGY 
LABORATORY – LID, UNIVERSIDAD PERUANA CAYETANO 
HEREDIA, Lima - Peru 
 




1. To use the lithium ratio as the gold standard for diagnosing bipolar 
disorder. 
2. To determine if the RPMI medium could be used instead of the 
Adenosine containing medium in the lithium rate method. 
3. To identify erythrocytes membrane transporters associated with lithium 
transport and correlate their function with bipolar disorder.  
 
Performed the Lithium ratio protocol proposed by Dorus et al. and 





Research Assistant, INTERNATIONAL POTATO CENTER (IPC), 
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Lima - Peru 
 
PROJECT:  Biological and molecular characterization of the geographical 
isolates of PoGV (Granulovirus) 
 
GOAL: To characterize genomic polymorphisms of geographical 
isolations of PoGV. 
 




1. To evaluate adult nymphs of whitefly to identify species by taxonomic 
key  and molecular biology 
2. To identify Bemisia tabaci (Gennadius) biotypes in order to know the 
biotype that prevails in Peru. 
 
PROJECT: Diagnosis of granulosis virus through PCR. 
 
GOAL: To develop a sensitive method based on PCR as a complement to 
the traditional techniques. 
 
PERFORMED THE FOLLOWING ASSAYS IN THE THREE 
PROJECTS: 
 Biological activity of the geographical isolations: lethal 
concentration, bioassays and breeding of plague insect.  
 Viral kinetics: counting of the viral multiplication inside each larvae 
making use of the Neubauer hemocytometer. 
 Molecular characterization: 
o Massive production of PoGV 
o Viral purification and DNA extraction 
o PCR using specific primers for apoptotic genes 
o Recovery of DNA fragments from agarose gels (Promega  kit). 
 Design of a specific primer for granulin gene: bioinformatic 
programs GeneFisher, ClustalX, Blast. 
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 Standardization of RAPDs to diagnose biotypes of whitefly. 
 Other:  
o Genetic transformation (Genetic Resources area). 
o Serology: NCM-ELISA and DAS-ELISA to detect main viruses 





Research Assistant, INTERNATIONAL  POTATO CENTER (IPC), 
Lima - Peru 
 
PROJECT:  Molecular characterization through RAPD-PCR of 18 
isolations of Beauveria brongnartii, Paecelimices Spp and Beauveria 
bassiana in order to control the weevil of Andean crops. 
 
GOAL: To understand the variability of fungus collection at molecular 
level and to cluster this isolation. 
 
PROJECT:  Search for a new entomopathogen to control Symmetrischema 
tangolias in Bolivia and Peru valleys. 
 
GOALS:  
1. To collect/identify new viral agents for S. tangolias control in the field 
and storage in Peru and Bolivia. 
2. To characterize the isolated viral pathogen through RFLP analysis. 
 
PROJECT:  Spatial distribution of Bemisia tabaci whitefly and Bemisia 
afer in Cañete valley. 
 
GOALS: 
1. To identify species of whitefly (Homoptera: Aleyrodidae). 
2. To study the seasonal variation and dissemination of B. tabaci and B. 
afer in sweet potato fields in Cañete valley. 
3. To study the distribution and dissemination of whitefly species in 
Peruvian coast.  
 




 Preparation of stock solutions to use in molecular entomology. 
 Multiplication of entomopathogenic fungi in PDA culture media. 
 Use of RAPD-PCR to differentiate isolations of entomopathogenic 
fungi. 
 Electrophoresis and silver staining of polyacrylamide gels. 
 Electrophoresis and ethidium bromide staining of agarose gels. 
 Bioassays and massive production of PoGV virus, isolated from 
S.tangolias, in P. operculella hostage. 
 Counting of granulovirus using the Neubauer hemocytometer. 
 Use of transmission electronic microscope (TEM) and scanning 
electronic microscope (SEM). 
 Purification of PoGV virus from S. tangolias. 
 DNA extraction from PoGV virus -S. tangolias. 
 Characterization of different isolations of PoGV by RFLP analysis. 
 Use of DNAstar program to design primers. 
 Use of DAS-ELISA technique to diagnose viruses in insects. 
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2014 Ferrer, P., Vega-Rodriguez, J., Jacobs-Lorena, M., Sullivan, DJ. [Effect 
of antimalarial iron chelator FBS0701 on Plasmodium falciparum 
mosquito stages]. To be submitted to Antimicrobial Agents and 
Chemotherapy 
 
2014 Ferrer, P., Castillo, R., Roy, C., Sullivan, DJ. [Dynamics of Plasmodium 
liver stage, hepcidin and iron in iron deficient mice]. To be submitted to 
Infection and Immunity 
 
2012 Ferrer, P., Tripathi, AK., Clark, MA., Hand, CC., Rienhoff, HY, Sullivan, 
DJ. 
[Antimalarial Iron Chelator, FBS0701, Shows Asexual and Gametocyte 
Plasmodium falciparum Activity and Single Oral Dose Cure in a Murine 





Sheen, P., Ferrer, P., Gilman, R., Christiansen, G., Gutiérrez, A., Sotelo., 
Evangelista, W., Fuentes, P., Rueda, D., Flores, M., Olivera, P., Solis, J., 
Pesaresi, A., Lamba, D., Zimic, M. [Role of Metal Ions on the Activity of 
Mycobacterium tuberculosis Pyrazinamidase]. American Journal of 




Sheen, P., Ferrer, P., López, J., Gilman, R., Fuentes, P., Valencia, E., 
Zimic, M. [Relationship between Pyrazinamide susceptibility and 
Pyrazinamidase kinetic parameters in Mycobacterium tuberculosis]. 








Ferrer, P., Castillo, R., Roy, C., Sullivan, D. [Iron compartmentalization 
regulates hepatic Plasmodium growth]. 
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Tripathi, A., Ferrer, P., Rienhoff, H., Sullivan, D. [Single oral dose cure 
of lethal P. yoelii with a new iron chelator in human clinical trials for iron 
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ADVANCES IN MALARIA: RESISTANCE TO EXISTING DRUGS 










Baldeviano,G., Barin,J., Lei, W., Talor, M., Ferrer, P., Chen, P., Legault, 
J., Ong, S., Zheng, D., Bedja, D., Gabrielson, K., Chatzidimitriou, D., 
Rose, N., and Cihakova, D. [Eosinophils promote myocarditis and dilated 
cardiomyopathy by enhancing Th17 responses].  
98
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J., Zimic., M. [Mycobacterium tuberculosis Pyrazinamidase: Association 
between enzymatic activity and the Pyrazinamide resistance level  and 
characterization of the metal binding properties]. 43
rd
 ANNUAL US-









Zegarra, O., Sporleder, M., Hualla, V., Ferrer, P. [Use of PCR to 
diagnose the granulovirus of Phthorimaea operculella potato tuber moth 
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middle-income countries: Results of a mapping project. World Health 









Collaboration in the systematization of technical work of the Payments for 
Environmental Services experiences. ASOCIACION QUECHUA-
AYMARA, ANDES (CUSCO – PERU) 
 
PROJECT: Ecosystem Sub-Global Assessment of the Vilcanota Sub-
Region, developed by the Millennium Ecosystem Assessment Group. 
 
PROJECT: Conservation strategy of the agricultural diversity of Santo 
Tomas river basin (Peru) by the Payments for Environmental Services 







Advanced English Course. Included preparation for the “Certificate in 
Advanced English - CAE” from the University of Cambridge. 
171 
 





First Certificate in English (FCE). UNIVERSITY OF CAMBRIDGE- 
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